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ABSTRACT 
As the only effective treatment for HIV/AIDS, adherence to antiretroviral therapy (ART) is 
critical for successful treatment outcomes. Despite its open availability since the national rollout 
in 2004, adherence to ART has remained sub-optimal and the number of individuals shifted to 
the more expensive second-line therapy on steady increase. The literature reports more 
commonly on individual, psychological, and behavioural barriers to treatment. However, there 
has been a vast interest in the structural barriers that prohibit adherence to ART. In previous 
research, my colleagues and I identified the following structural barriers to treatment adherence: 
stigma-related barriers, the disincentives associated with disability grants, poor relationships with 
clinic staff, lack of privacy at clinics for counselling and treatment, transport difficulties in 
travelling to the clinic, long patient waiting times, food insecurity, substance abuse and the 
absence of substance abuse programmes, and migration. The data were arrived at by means of 
triangulated qualitative interviews obtained from patients, patient advocates, doctors, and nurses. 
Together, these qualitative data formed phase 1 of this study. The next step or phase 2, in this 
research was to develop a valid and reliable quantitative instrument based on these qualitative 
data.  
Therefore the primary aim of the study presented in this thesis was to identify the 
underlying factor structure of four scales aimed at measuring adherence at two levels namely, 
adherence to clinic attendance, and adherence to pill-taking. After sampling a group of almost 
300 persons living with HIV (PLWH) four valid and reliable scales assessing structural barriers 
to adherence to ART were derived at with Cronbach alpha coefficients ranging from 0.87 to 
0.91. For each scale, a general or higher order factor was determined by means of hierarchical 
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transformation suggesting that the items on each of the scales were dominated by a single 
underlying factor.  
The findings of this research suggest that it is possible to assess the structural barriers to 
adherence that PLWH face on a daily basis. With a proper means, such as these scales, to assess 
structural barriers to adherence to ART clinicians may be able to identify patients who are likely 
to default and provide adequate attention to the most distressing barriers.  
Keywords: Antiretroviral therapy, structural barriers, adherence, HIV/AIDS 
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OPSOMMING 
Antiretrovirale terapie (ART) is die enigste effektiewe behandeling teen MIV/Vigs.Behandeling 
met hierdie terapie kan slegs suksesvol voltooi word indien die medikasie ononderbroke en 
gereeld geneem word. Alhoewel medikasie vrylik beskikbaar was sedertdien die nasionale 
bekendstelling in2004, het die aantal individue watna duurder tweede lyn terapie oorgegaan het 
toegeneem. Die volhoubaarheid van ART was dus nie optimaal nie. Dit kan toegeskryf word aan 
individuele -, sielkundige - en gedragstruikelblokke tydens behandeling wat tans baie aandag 
geniet in die literatuur.Om by te voeg, strukturele hindernisse tot ARTgeniet ook tans baie 
aandag. Met hierdie as agtergrond, was die primêre doel van die studie om die onderliggende 
faktor struktuur van vier skale wat strukturele hindernisse tot ART op twee vlakke meet, naamlik 
getroue kliniek bywoning en neem van medikasie,te indentifiseer. 
Ons het met vorige navorsing die volgende strukturele hindernissetot ART geidentifiseer: 
stigma-verwante hindernisse, hindernisse wat verband hou met ongeskiktheidstoelaes, swak 
verhoudings met kliniek personeel, die gebrek aan privaatheid by klinieke in terme van berading 
en behandeling, vervoerprobleme, lang wagtyevir pasiënte, voedselonsekerheid, dwelmmisbruik 
en die afwesigheid van middelmisbruik-programme, asook migrasie. Data aangaande 
bogenoemde strukturele hindernisse is ingesamel deur middel van kwalitatiewe onderhoude met 
pasiënte, pasiënt-advokate, dokters en verpleegsters (fase 1). Gedurende fase 2 van hierdie studie 
is„n geldige en betroubare kwantitatiewe instrument op grond van hierdie kwalitatiewe data 
ontwikkel.  
„n Steekproef van ongeveer 300 MIV-geinfekteerde individuehet deelgeneem. Vier 
geldige en betroubare skale is ontwikkel ten opsigte van die assessering van strukturele 
hindernisse in terme van gereelde gebruik van antiretrivale middels, met Cronbach alpha 
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koëffisiënte tussen 0.87 en 0.91.Vir elke skaal is 'n algemene of hoër-orde faktor bepaal deur 
middel van hiërargiese transformasie wat daarop dui dat die items op elk van die skale 
gekenmerk is deur „n enkele onderliggende faktor.  
Ons bevindinge dui daarop dat dit moontlik is om die strukturele hindernisse wat MIV 
individue daagliks tot ART ondervind te meet.  Met die gebruik van hierdie skale sal klinicidus 
in staat wees om pasiënte te identifiseer wat moontlik van ART sal afwyk of die terapie sal staak 
met die klem op mees onstellende hindernisse. 
Sleutel woorde: Antiretroviraleterapie, strukturele hindernisse, volhoubaarheid, MIV / 
Vigs 
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CHAPTER 1 
INTRODUCTION 
1.1 Introduction and rationale for the present study 
The success of antiretroviral therapy (ART) in treating HIV-AIDS has rendered the disease 
as no longer life-threatening but a chronic and manageable condition (Nischal, Khopkar, & 
Saple, 2005). However, adherence to ART remains an obstacle to treatment success (Mills et al., 
2006). Adherence to ART is obstructed by numerous psychological, individual, and structural 
barriers. The aim of this study was to use previously determined structural barriers to adherence 
to ART, and develop an appropriate tool with which to assess such barriers. 
1.1.1 HIV/AIDS: Global figures. 
At present, the HIV/AIDS epidemic has spread to almost 60 million people worldwide, 
with an estimated 25 million having died from HIV-related causes (Joint United Nations 
Programme on HIV/AIDS [UNAIDS], 2010  ). An estimated 33.4 million people were living 
with HIV in 2008, of which 430 000 were children born with HIV. The number of individuals 
newly affected by HIV continues to dominate the actual numbers on treatment. According to 
UNAIDS (2010) five people are infected with HIV for every two that have just started treatment. 
By the end of 2008, more than 4 million people living in low and middle income countries had 
access to HIV treatment. However, global coverage continues to remain low with only 42% of 
the global total having had access to treatment in 2008(UNAIDS, 2010).  
1.1.2 HIV/AIDS: Sub-Saharan Africa. 
Sub-Saharan Africa remains the region most affected, accounting for 67% of the global 
population living with HIV (UNAIDS, 2010). Approximately 1.9 million new HIV infections 
occurred in this region during 2008, bringing the total up to 22.4 million persons living with HIV 
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(PLWH) in Sub-Saharan Africa. Despite stabilization of the epidemic over most of Sub-Saharan 
Africa, Southern Africa still bears a disproportionate share of the global total infected and living 
with HIV. In almost all of the nine countries in Southern Africa, the adult HIV prevalence is 
greater than 10% (UNAIDS, 2010). 
1.1.3 HIV/AIDS: South Africa. 
In 2009 an estimated 5.7 million people were living with HIV in South Africa, making it 
the largest population of PLWH worldwide (UNAIDS, 2010). Despite a decline in the rate of 
new infections (Adult HIV prevalence decreased from 5.8% in 2001 to 5.2 % in 2008), the 
number of PLWH increased in 2008(UNAIDS, 2010).  
1.2 Stages of Infection 
Persons living with HIV usually endure a number of stages of infection. The World 
Health Organization (WHO) describes four stages of infection (World Health Organization 
[WHO], 2010). Individuals in WHO stages one and two are fairly asymptomatic. Persons in 
WHO stage three experience weight-loss, diarrhoea, and relatively severe oral infections. 
Persons in WHO stage four suffer from full-blown AIDS. Individuals in stage four are estimated 
to die within a year or two if they are not receiving antiretroviral therapy (ART) (Dorrington, 
Johnson, Bradshaw,& Daniel, 2006).   
1.3 Antiretroviral therapy (ART) 
HIV/AIDS is eventually fatal without treatment (Dorrington et al., 2006). In 2008, 44% 
of the population in need of antiretroviral treatment had access to it. Despite the vast 
improvement since the 2% coverage only five years prior, the national rollout has yet to reach all 
in need. ART has substantially improved health outcomes, as HIV/AIDS is now far from a 
terminal illness and rather a manageable chronic illness (Nischal et al., 2005). According to the 
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WHO (2010) patients adhering fully to ART are less likely to transmit the disease to sexual 
partners. However, patients with unrecognized HIV illness and infection contribute greatly to the 
on-going sexual transmission. Approximately 495 000 individuals are expected to die due to 
AIDS related death by the end of 2010 in South Africa, without ART (Dorrington, Bradshaw, 
Johnson, & Budlender, 2004). ART thereby has the potential to control and decrease AIDS 
related morbidity and mortality (Centre for Disease Control and Prevention [CDC], 2001). 
However, advances in treatment rely on adequate adherence as well as sufficient access to 
treatment.  
The overarching goals of antiretroviral therapy are aimed at reducing patient morbidity 
and mortality (Garcia & Cote, 2003). With proper use of the medication patients should 
experience fewer HIV related illnesses. Patients‟ CD4 counts should gradually rise and remain 
above 200 copies/ml, which is the baseline count. The viral load in the patient‟s blood should 
become nigh undetectable (< 400 copies/ml) and continue to remain undetectable whilst on ARV 
therapy.  
1.4 Barriers to adherence 
A considerable amount of research has been focused on individual-level barriers to 
adherence to ART. In particular focus has been given to depression (Seldjeski, Delahanty, & 
Bogart, 2005), health literacy, forgetfulness (Mills et al., 2006), substance abuse (Kalichman, 
Rompa et al., 2001; Weiser et al., 2003; Gordillo, Del Amo, & Soriano, 1999), low self-efficacy 
(Berg, Michelson & Safren, 2007), fear of disclosure (Ware, Wyatt & Tugenberg, 2006) and 
emotional distress (Kalichman, Ramachandran & Catz, 1999). 
Despite a steadily emerging literature, structural barriers to adherence have received 
much less attention. Shriver, Everett and Morin (2000) have described structural factors as broad 
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based forms of social construction which include legal, political and environmental factors acting 
as barriers or facilitators to peoples actions. Various authors have categorized these barriers 
differently. Kagee, Remien, Berkman, Hoffman,  Campos  and Swartz  (2010) divide structural 
barriers into three main groups namely, (1) institution-related factors, (2) poverty-related factors 
and (3) culturally and politically-related factors. Mills et al. (2006) group these barriers into (1) 
patient related factors, (2) beliefs about medication,  and (4) daily schedules. 
Structural barriers to a large extent impede patient adherence, as these barriers cause 
obstructions to patients‟ daily routines. Studies that prompted this research, conducted by 
Coetzee, Kagee and Vermeulen (2011), Kagee and Delport (2010), and Nothling (2009) 
identified structural barriers to adherence from the perspectives of three key stakeholders. Health 
care workers (doctors and nurses), patients, and patient advocates were asked to provide their 
insights into the possible barriers patients may face when it came to (a) attending clinic 
appointments and (b) the actual taking of their medication. The studies were qualitative in nature 
and the results showed that patients face an array of debilitating structural barriers that include: 
waiting times at the hospital which interferes with working hours, overcrowding at the clinic, 
language barriers with clinicians, lack of counsellors especially skilled counsellors, stigma, non-
disclosure, interference with daily routines, transport difficulties, migration, disability grants that 
served as disincentives, psychosocial issues that include substance abuse and a lack of support 
programs for this, food insecurity and a lack of privacy. These studies collectively formed Phase 
1 of this research and the basis on which the scales (Phase 2) were developed.  
Phase 2 of this research has attempted to quantify these issues by means of scale 
development. Ideally, the scales will provide clinicians with a tool to allow for early 
identification of barriers that may impede adherence in new enrollers of ART. Early detection 
Stellenbosch University  http://scholar.sun.ac.za
5 
 
will provide an opportunity to limit the number of patients that drop out of care or progress to 
second or third line treatment.  
1.5 Motivation for the present study 
An emerging literature including the data collected from Phase 1 of this study, suggests 
that structural barriers greatly impede adherence. However, no attempt has been made thus far to 
measure these barriers in a clinical setting. With the overwhelming numbers of patients seeking 
treatment at public health hospitals, it has become vital to ensure that those who are already on 
treatment remain on treatment. The knowledge gained on structural barriers that impede 
adherence served as a guide to develop an instrument to determine what barriers patients face 
that result in poor adherence rates. With a proper means to assess the salience of these barriers, 
clinicians will be able to identify those barriers which create the greatest obstacle to care.  
1.6 Aims and objectives 
The aim of the present study was to identify the underlying factor structures of a series of 
scales assessing structural barriers to ART as identified in Phase 1 of the research. Phase 1 of the 
study has already been conducted and involved in depth qualitative interviews with key 
stakeholders. Several barriers were identified. Phase 2 was therefore aimed at quantifying these 
findings by developing a valid and reliable psychometric instrument that can be used by 
clinicians to measure the most salient of these barriers, and identify those patients who face 
multiple structural barriers to adherence. 
1.7 Overview of chapters 
Chapter 2 provides an overview of the current literature regarding antiretroviral therapy, 
adherence, and measuring adherence to ART. Furthermore, the review identifies both individual 
and structural barriers to adherence. Finally, the conceptual framework within which the study is 
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thought to exist is explained. Chapter 3 describes the methodology that was followed in the 
present study, including the research design, the selection of participants, data collection, and the 
data analysis procedure. Chapter 4 discusses the results found in the present study. Chapter 5 
involves a discussion of the results, including the implications of the present study‟s findings and 
directions for future practice and research. 
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CHAPTER 2 
LITERATURE REVIEW 
 2.1 Antiretroviral Therapy (ART) 
Since the introduction of antiretroviral‟s (ARVs) in the 1990‟s, treatment and care for 
PLWH has completely revolutionized (Hardon et al., 2006). The latest indicators of patients on 
treatment in South Africa shows that 919, 923 people were receiving ART by the end of 
November 2009 (UNGASS, 2010). This number excludes the additional 51, 633 people 
receiving treatment from private clinics and NGO‟s. This number is substantially larger than the 
140, 000 persons that were estimated to be on treatment only three years prior (Dorrington et al., 
2006). The majority of these patients remain on first-line therapy. However, the numbers failing 
at first line treatment are of concern. Médecins Sans Frontières (MSF, 2010) found that 14% of 
the patients supported by the HIV/AIDS programme they helped initiate in Khayelitsha (a 
township in the Western Cape) in 2005 had to be moved to second-line therapy after only five 
years on treatment. Second-line therapy is far more expensive than first line and particular 
concern has been raised to developing resistance to second-line regimens in third world 
countries,  especially since monitoring of patient viral loads is either sub-standard or absent (Fox, 
Ive, Long, Maskew & Sanne, 2010). 
2.2 Antiretroviral Regimens 
Early enrolment into ART is critical for receiving the most out of treatment and to reduce 
complications. Mortality rates range between 3% -26% amongst adult PLWH during the first 
year of ART, with most deaths occurring within the first few months (WHO, 
2010).Antiretroviral therapy guidelines have changed somewhat since those recommended by 
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the WHO in 2006. The 2010 edition of the ART guidelines as described by the WHO 
recommends that two key changes be made: 
1. Commencement of treatment. 
In the 2006 guidelines, patients with a CD4 count < 200 cell/mm3 were started on 
treatment. In the 2010 ART guidelines, all patients (including pregnant women and adolescents) 
with a CD4 < 350 cells/mm3 are recommended to start treatment immediately. If CD4 count 
testing is not available, those with a WHO clinical stage of three or four are intended to start 
treatment as well (WHO, 2010). 
2. Calls to reduce the use of Stavudine (d4T). 
Fifty-six percent of ART regimens continue to use Stavudine (d4T), especially in 
resource-limited settings as alternatives such as Zidovudine (AZT) and Tenofovir disoproxil 
fumarate (TDF) remain more expensive. It is recommended strongly by the WHO that d4T be 
progressively phased out of HIV regimens (WHO, 2010). Recent studies (e.g. Kline et al., 2008) 
have shown that prolonged exposure to d4T has severe side effects. Disfiguring, and toxic side 
effects such as lipodystrophy, peripheral neuropathy, and lactic acidosis have been identified and 
are painful as well as life threatening to PLWH (WHO, 2010). The following two regimens exist 
for newly infected (naïve) patients. 
2.2.1 First-line Therapy – Schedule One. 
The following regimen differs for pregnant women who are HIV positive, as well as for 
those individuals with either a TB (tuberculosis) or HBV (hepatitis B virus) co-infection.   
Unless contraindicated, all patients commence therapy on:  
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1. Zidovudine (AZT); 300 mg every 12 hours orTenofovir disoproxil fumarate(TDF) 
with 
2. Lamivudine (3TC); 150 mg every 12 hours orEmtricitabine (FTC) and 
3.  Efavirenz (EFV); 600 mg at night (or 400 mg if < 40 kg) or Nevirapine (NVP); 200 
mg daily for 2 weeks, followed by 200 mg every 12 hours. 
2.2.2 Second-line Therapy –Schedule Two. 
Patients who do not follow treatment as prescribed, and consequently continue to fail 
virologically may ultimately be changed to second line therapy, or schedule two treatment 
(WHO, 2010). Patients commence schedule two as follows:   
If either Stavudine (d4T) or Zidovudine (AZT) have been used in first line therapy then use:  
TDF with 3TC (or FTC) with ATV/r or LPV/r. 
If TDF had been used in first-line therapy then use: 
AZT with 3TC (or FTC) with ATV/r or LPV/r (Lopinavir/ritonavir). 
2.3 Adherence to ART 
Adherence to antiretroviral therapy is currently the greatest predicator of treatment 
success for people who are able to access the drugs (Mills et al., 2006). However, adherence to 
ART remains a key challenge to HIV/AIDS care worldwide (Van Dulmen et al., 2007; Weiser et 
al., 2003).  
Schonnesson, Diamond, Ross, Williams, and Bratt (2006) define adherence in terms of 
dose adherence, schedule adherence and dietary adherence. Dose adherence involves the number 
and proportion of dosages to be taken. Schedule adherence refers to the taking of dosages at the 
correct times daily. Lastly, dietary adherence involves taking doses with the correct foods daily. 
In addition to regimen adherence, the monthly attendance of clinic appointments is referred to as 
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adherence to care. Non-adherence may therefore involve skipping doses, not taking the treatment 
at the correct times daily, taking the wrong doses, or prematurely terminating the treatment 
(Miller, 1997). 
High levels of adherence are required for effective viral suppression, to prevent resistance 
to drugs, to limit disease progression, and to prevent death (Paterson et al., 2000). According to 
Van Dulem et al. (2007) adherence amongst patients with chronic conditions such as HIV, 
diabetes, and hypertension is reportedly far lower than adherence amongst patients with acute 
illness such as flu or appendicitis. The success of the treatment hinges almost entirely on the 
patients pill-taking behaviour. More than 95% adherence to ART is required for optimal 
treatment success (Paterson et al., 2000; Bangsberg, 2006). However, studies have  shown that 
patients receiving more potent doses of treatment drugs experience virological suppression at 
lower rates (70%) of adherence (Bangsberg, 2006). To achieve virological suppression it is 
required that patients not miss more than three doses a month (Golin et al., 2002). These seem 
like manageable requirements. However the regimen is complicated (Golin et al., 2002), and 
often results in dietary complications (Schonnesson et al., 2006) and possible side effects 
(Weiser et al., 2003; Hardon et al., 2007).   
As mentioned previously adherence to care is one of the greatest obstacles facing persons 
on ART. Authors such as Machtinger and Bangsberg (2007), in their review on adherence to 
ART, have highlighted the concerns about providing treatment to PLWH in resource-limited 
settings. Amongst these concerns was that, providing treatment for PLWH in resource-limited 
settings would lead to widespread resistance. The next section provides evidence of adherence 
rates in resource-limited settings being comparable to those in resource-rich settings.  
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2.3.1 Adherence in resource-limited settings 
Since 2001, the Western Cape Department of Health and Médecins Sans Frontières 
(MSF) have worked together to provide ART for persons living with HIV in Khayelitsha, a 
township near Cape Town (Coetzee et al., 2004). The rationale behind this initiative rested 
largely on providing evidence that persons living with HIV in resource-limited settings were able 
to achieve similar adherence rates to persons living with HIV in developed countries.  The 
success of this project was mainly as a result of the strict criteria patients had to meet before 
enrolling (Coetzee et al., 2004). Only patients who resided in the township, had disclosed to 
another person and who attended clinic appointments regularly were considered for treatment. 
Furthermore, only patients who met the WHO stage three and stage four classification criteria 
and who had a CD4 cell count of less than 200 cells/mm3 were eligible on clinical grounds.  
Patients received social support in the form of counselling sessions with trained counsellors, and 
peer support groups aimed at identifying any obstacles to care that patients may have been 
experiencing. Patients also received material support in the form of pill-boxes, drug-
identification charts, diaries and educational materials to explain the risks and benefits of ART. 
The results of the study were comparable to those of developed countries. Patients showed 
excellent adherence evident with the suppression of viral replication and an almost perfect rate of 
patient retention to care (Coetzee et al., 2004).   
Other studies conducted in resource-limited settings, such as Uganda (Weidle et al., 
2006), Rwanda (Demeester et al., 2005), and Haiti (Koenig, Leandre, & Farmer, 2004), showed 
that high rates of adherence were achievable. Moreover, a study conducted by Orrell, Bangsberg, 
Badri, and Wood (2003), showed that there was no association between socioeconomic status 
and adherence to ART.  
Stellenbosch University  http://scholar.sun.ac.za
12 
 
Much of the data collected in the above mentioned studies were confined to experimental 
settings where patients had to meet strict criteria. The intensity of the support received under 
these circumstances will most likely not reach the non-experimental setting, which is the large 
numbers of patients seeking HIV treatment and care.  However, although these studies point to a 
high level of commitment to medication adherence, there persists an array of barriers (discussed 
later on) that impede on treatment success (Tuller et al., 2009).  
2.4 Measuring Adherence to ART 
Various studies have tried to measure (non-) adherence (Gill, Hamer, Simon, Thea, & 
Sabin, 2005; Turner, 2002; Gagne &Godin, 2005; White et al., 2006; Llabre et al., 2006; Johnson 
et al., 2007). Simoni et al., (2006) suggest that adherence to ART can be measured by either 
direct or indirect methods.  
2.4.1 Direct Methods. 
2.4.1.1 Biological markers. An assessment of biological markers involves the analysis of 
active drug metabolites or other indicators in blood, urine or other bodily fluids. These methods 
confirm whether active drug ingestion and digestion have occurred (Simoni et al., 
2006).Biological markers (e.g. blood or urine) are not always indicative of medication non-
adherence as the influence of medication on these markers are often not significant over short 
periods of time and may be influenced by other forms of medication as well (Miller & Hays, 
2000).  
2.4.2 Indirect methods. 
2.4.2.2 Patient self-report. Patient self-report is one the most frequently used measures of 
adherence in the literature (Nieuwkerk & Oort, 2005; Ferradini et al., 2006; Ross-Degnan et al., 
2010; Chalker et al., 2010). Self-report questionnaires are virtually trouble-free to administer and 
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remain a cost effective method of data collection (Ross-Degnan et al., 2010). However, patient 
self-report tends to overestimate adherence more than any of the other methods used (Golin et 
al., 2002; Arnsten et al., 2001). According to Gagne and Godin, (2005) self-report inaccuracy 
occurs as a result of two factors. Firstly, there exists an inadequate operationalization of adherent 
or non-adherent behaviour. The second factor that contributes to inaccuracy in self-report is not 
applying rigorous enough measurement techniques so as to reduce factors such as memory 
errors, social desirability and recall bias (Gagne & Godin, 2005; Turner, 2002). In a study 
conducted by Chalker et al., (2010), when compared to clinical records patients had 
overestimated their adherence by more than 14%.  
2.4.2.3 Pill counts. Pill counts may be defined as the percentage of days that patients 
receiving ARV‟s took their medication as prescribed based on pill counts conducted at each 
clinic visit (Chalker et al., 2010). Like self-reports pill counts also tend to overestimate 
adherence, as it has been reported that patients often dispose of their medication (Gagne & 
Godin, 2005), or forget to bring their pill bottles to clinic visits (Turner, 2002). Patients also 
often combine various medications into a single dosage container, and will subsequently forget 
to bring the correct tablets to the clinic appointments (Gagne & Godin, 2005). 
2.4.2.4 Electronic drug monitoring. Electronic devices that monitor pill counts like, 
Medication Events Monitoring System (MEMS) is a more objective measure of adherence than 
patient self-report (Turner, 2002). The system works by means of an electronic chip that is 
inserted into the cap of pill bottles and records the number of doses taken every time the bottle is 
opened (Turner, 2002). However, even such high-tech measures inaccurately measure patient 
adherence as the chip may malfunction (Turner, 2002), and patients may remove more pills from 
the bottle than they are supposed to which is termed, “pill-dumping” (Gagne & Godin, 2005).In a 
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study conducted by Honghu et al., (2001) multiple measures of adherence were assessed and 
MEMS was reported to underestimate adherence. However, when compared to self-report 
measures and pill counts electronic drug monitoring is a much more reliable measure of 
adherence (Chalker et al., 2010). The latest innovation in electronic drug monitoring is the 
Wisepill device (www.Wisepill.com). This device is no larger than a wallet and transmits signals 
to the clinician via cellular networks each time a patient opens the device to take a pill. The 
signals are transmitted in real-time meaning that the clinician is able to see exactly when a 
patient is opening the device to take their medication. Each time the device is opened the action 
is recorded and tracked in an online chart (www.massgeneralmag.org). The device has been pilot 
tested amongst 10 Ugandan individuals for a period of six months in a study by Haberer et al., 
(2010). Due to battery failure and signal interruptions some of the results of the study were 
compromised. However, on average the results obtained from the Wisepill device were 
comparable to those achieved through the MEMS system (Haberer et al., 2010). 
2.4.2.5 Pharmacy refill records. Pharmacy refill records have been cited as another 
measure of adherence (Osterberg &Blaschke, 2005; Bisson et al., 2008; Ross-Degnan et al., 
2010; Chalker et al., 2010). This method of measuring adherence is useful with electronic 
pharmacy records as manual dispensing records are often incomplete (Ross-Degnan et al., 2010). 
In a study conducted by Bisson et al. (2008) pharmacy refill records were as accurate as CD4 
counts for detecting virological failure in patients and were thus deemed capable of predicting 
future virological failure.  
In the absence of a gold-standard various methods of assessment are used to measure 
adherence throughout studies most of which have been found to overestimate adherence (Gagne 
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& Godin, 2005). It may therefore be essential that future research focus on adequately defining 
adherence. 
2.4.2.6 Clinic attendance. Although not a measure of pill-taking adherence the 
consistency of attending clinic appointments has also been used as a measure of adherence 
(Ross-Degnan et al., 2010; Chalker et al., 2010). In a study conducted by Ross-Degnan et al. 
(2010), over 19% of the patients they followed during the course of the study had missed 
multiple clinic visits, despite self-report clinic adherence rates of over 70%. Clinic attendance 
was significantly associated with a patients weight gain, however not significantly associated 
with an increased CD4 count. In the study conducted by Chalker et al., (2010) a number of health 
facilities formed part of their study to assess different measures of adherence. Although 
adherence to clinic attendance ranged between 70% - 90% at most of the facilities, some 
facilities had clinic adherence rates as low as 14%. Ross-Degnan and colleagues (2010) argue 
that missed clinic appointments are fairly easy to ascertain from clinic records and that this 
method of measuring adherence may pick up on inconsistencies in clinic attendance fairly 
quickly and identify those patients that may need adherence counselling. 
2.5 Barriers to adherence to ART 
Barriers to ART can be grouped as either individual barriers (Mills et al., 2006) to 
adherence, or as structural barriers to adherence (Kagee et al., 2010; Coetzee et al., 2011; Kagee 
& Delport, 2010). The differences between these two groups are explained below. 
2.5.1 Individual barriers. More commonly reported in the literature than structural 
barriers to adherence, are individual barriers to adherence to ART. These barriers are 
predominantly psychological and behavioural in nature, and have for the most part been 
identified through patient self-report (e.g. Mills et al., 2006). The WHO (2003) groups these 
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barriers into three factors namely, regimen characteristics, patient characteristics, and the 
relationship between the provider and patient. The following barriers have been identified as 
individual determinants of adherence; Perceived social support (Holstad, Pace, De, & Ura, 
2006); substance abuse (Palepu et al., 2004; Sanjobo, Frich & Fretheim, 2008; Dahab et al., 
2008; Kip, Ehlers & Van der Wal, 2009; Tucker et al., 2004); disturbance in mental health, 
largely depression (Kilbourne et al., 2005); forgetfulness (Chesney et al., 2003), sleeping through 
dosages, adverse side effects (Davies et al., 2006),  the relationship with the  healthcare provider 
(Kalichman et al., 1999); beliefs about medication (Remien, Hirky, Johnson, Weinhardt, Whittier 
& Minh Le, 2003) and stigma (Brown et al., 2003).  
Mills et al. (2006) conducted a meta-analysis of  barriers and facilitators to adherence, as 
reported by patients, and categorized them into (1) patient related factors, (2) beliefs about 
medication, (3) Interpersonal  and (4) Daily schedules. The analysis draws on 37 qualitative and 
47 quantitative studies regarding barriers and facilitators to adherence. The barriers were 
grouped into those identified in developing countries and those identified in developed countries 
and are summarized in the Table 1 below. 
Table 1 
 Individual barriers to adherence identified in developed and developing countries 
Category Identified in developed countries Identified in developing countries 
Patient-
related factors 
Fear of disclosure and taking 
medication in public 
Substance addiction 
 Depressed, hopeless, or overwhelmed 
feelings 
Forgetfulness 
 A concurrent addiction Financial constraints 
 Forgetting to take pills on time Fear of disclosure 
 Suspicious of treatment or medical 
establishment 
Treatment instructions are complicated 
 A natural approach is preferred Concurrent disease or illness, including 
malnutrition 
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 Treatment is a reminder of HIV status Treatment compliance 
 Wanting to take control again  
 Treatment instructions are 
complicated 
 
 Doubts about HIV status  
 Lack of self-worth  
 Financial constraints  
 Homeless  
 Having a concurrent illnesses  
   
Beliefs about 
medication 
Side effects Side effects 
 Complicated regimens Regimen too complicated 
 Concerns about taste, size, dosing 
frequency, and/or pill count 
Doubts about efficacy of treatment 
 Doubting the efficacy of HAART Uncertain about long term effects 
 A decreased quality of life Concerns about taste, size, and 
frequency of dosing 
 Uncertain about long-term effects Feeling fine or healthy 
 Unwanted changes in body image Decreased quality of life 
  Uncertain about  long-term effects of 
HIV treatment 
   
Schedule 
adherence 
Disruptions in routine or having a 
chaotic schedule 
Interference with work and family 
responsibility 
 Finding treatment  difficult to 
incorporate with responsibilities 
Not receiving enough tablets 
 difficult to balance dietary 
requirements needed for treatment 
Away from home too long at a time 
 Oversleeping and missing dose Too busy to comply with treatment 
requirements 
 Away from home and not taking 
medication with 
Trouble incorporating work and family 
responsibilities with HAART 
 Too distracted or busy Traveling long distances to receive 
treatment 
 No time to refill prescriptions, or other 
pharmacy-related problems 
Running out of medications or having 
an irregular supply 
 Particular difficulty with middle-of-
the-day or morning dose 
Too busy or distracted to properly 
comply 
   
Interpersonal Lack of trust for healthcare-provider  
 Social isolation  
 Negative publicity regarding treatment 
or the medical establishment 
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 Poor or discouraging social network  
 
2.5.2 Structural barriers. Individual barriers to adherence to ART have been well 
researched and documented within the literature. However, the extent to which social, economic, 
institutional, political, and cultural aspects of larger social structures (Shriver, Everett & Morin, 
2000; Sumartojo, 2000) influence adherence have not been emphasized enough. Among the first 
South African studies focusing on structural barriers to adherence to ART included a review by 
authors, Kagee, Remien, Hoffman, Campos, and Swartz (2010); and empirical investigations by 
authors, Coetzee, Kagee and Vermeulen (2011); Kagee and Delport (2010) and Nothling (2009). 
Kagee, Remien et al., (2010) categorise structural barriers into: Institution-related barriers, 
poverty-related and finally, cultural and politically related barriers.  
2.5.2.1 Institution-related barriers. 
2.5.2.1.1 The healthcare environment. One of the chief barriers to clinic attendance are 
health care facilities that are overburdened and characterized by inadequate infrastructure and 
necessary resources (Smit, 2004), insufficient staff (Benatar, 2004; WHO, 2006), and large 
patient numbers attending clinics for treatment (MSF, 2007).  The role of providing care to 
PLWH has been reported an overwhelming task and forced many professional nurses to seek 
work in other countries (Smit, 2004). In Coetzee et al., (2011) and indicated in other studies (e.g. 
Gueritault-chalvin et al., 2000;  Swartz & Dick, 2002; Smit, 2004; Murray et al., 2009) 
overburdened public health care clinics led to burn-out and work frustration among health care 
workers. These unsatisfactory conditions put significant strain on the patient-provider 
relationship (Cole & Abel, 2000; Swartz & Dick, 2002). In Coetzee et al. (2011) nurses reported 
observing some of their work colleagues behaving unsympathetically or even impatiently 
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towards patients. Patients reported feeling alienated and were therefore reluctant to attend the 
clinic.  
2.5.2.1.2 Lack of privacy at clinics. Despite concerted efforts to combat the restrictions 
on public health care post-apartheid (Coovadia, Jewkes, Barron, Sanders & McIntyre, 2009), the 
healthcare system is still failing to provide adequate facilities to offer basic services to persons 
seeking care. In the context of large scale stigmatization against persons living with HIV, the 
need for privacy and confidentiality at clinics and hospitals has become of even greater 
importance.  In Coetzee et al. (2011) a nurse reported that the lack of privacy at the clinic meant 
that patients were unable to communicate the deeper level issues to adherence that they were 
facing which disrupted the patient-provider relationship (Coetzee et al., 2011; Kagee et al., 
2010).  
2.5.2.1.3 Long waiting times at the clinics.  Several studies have reported long waiting 
times at the clinic to be a disincentive to clinic attendance for most patients (Hardon et al., 2007; 
Dahab et al., 2008; Roura et al., 2009; Coetzee et al., 2011; Kagee & Delport, 2010). In a study 
conducted by Hardon and colleagues (2007), the average time spent at the clinic for most 
patients was six hours. The most important consequence of these long hours was the risk of job 
dismissal as many of the patients had not yet made their HIV status known to their employers.  
2.5.2.2 Poverty-related structural barriers. 
2.5.2.2.1 Transport difficulties. Transport-related barriers to adherence was a salient 
theme throughout the literature (Weiser et al., 2003; Jaffar et al., 2005; Mills et al., 2006; 
Mshana et al., 2006; Mukherjee et al., 2006; Miles, Clutterbuck, Seito, Sebego & Riley, 2007; 
Maskew, MacPhail, Menezes & Rubel, 2007; Hardon et al., 2007; Posse, Meheus, Van Asten, 
Van der Ven & Baltussen, 2008; Tuller et al., 2009; Coetzee et al., 2011; Kagee & Delport, 
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2010). Most patients attending public health clinics do not have private transport and rely 
completely on public transport which is for the most part expensive, unsafe and unavailable in 
some areas (Kagee, Le Roux & Dick, 2007). In the study by Kagee and Delport (2010), patient 
advocates indicated that indirect routes to the clinic resulted in patients having to travel several 
kilometres further to the clinic despite weather conditions or feeling physically ill. Several 
studies afforded the cost of transport to greatly impede patients‟ willingness to get to the clinic 
(Hardon et al., 2007; Weiser et al., 2003; Tuller et al., 2009; Ware, 2009). Taxi riots and unrest 
presented further obstacles to clinic adherence (Coetzee et al., 2011). According to Kagee et al., 
(2007) poor access to safe and adequate transport poses a barrier to adherence for many persons 
receiving ART. 
2.5.2.2.2 Food insecurity. Weiser and colleagues (2010) were among the first authors to 
investigate the ways in which food insecurity obstructs adherence. The authors found that food 
insecurity and hunger presented a direct obstacle to daily adherence. In particular, the fear of 
hunger and food insecurity caused patients to delay treatment initiation or to discontinue 
treatment. The study concluded five ways in which food insecurity impedes on adherence. These 
were, increased hunger associated with the taking of ARVs, the side effects associated with 
taking food on an empty stomach, the lack of counselling required to emphasize the need to take 
ARVs with food, the constant negotiation between satisfying healthcare costs or food costs, and 
either forgetting or being too busy searching for food or work to be able to take ARVs. The 
above mentioned consequences of food insecurity are in accordance with several other studies 
(Weiser et al., 2003; Nachega et al., 2006; Hardon et al., 2007; Sanjobo, Frich & Fretheim, 2008; 
Tomlinson, Rohleder, Swartz, Drimie & Kagee, 2010; Gillepsie & Drimie, 2008; Ivers, Chang, 
Jerome & Freedberg, 2010). 
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2.5.2.2.3 Substance abuse. Many studies have reported substance abuse as an individual 
barrier to adherence (e.g. Holstad et al., 2006; Mills et al., 2006 & Tucker et al., 2004). However, 
in the context of there being limited mental health and substance abuse programs for people 
living in resource constrained settings, Coetzee et al. (2011) and Kagee et al. (2010) identified 
the lack of substance abuse programmes in resource-constrained settings as a structural barrier to 
adherence.  
2.5.2.2.4 Disability grants as disincentives to adherence. An HIV diagnosis in South 
Africa is tied with eligibility for a government-funded monthly disability grant (Nattrass, 2006a, 
b). Disability grants are given to those patients with a CD4 count of less than 200 cell/mm3 and 
deemed incapable of working (Nattrass, 2006a). However, when disability grants are linked to 
biological indicators like, low CD4 counts and high viral loads, many patients would terminate 
their treatment in order to re-qualify for the grant (Nattrass, 2006a). According to De Paoli, 
Grønningsæter, and Mills (2010), 10% of the participants in their study agreed that it was 
common place for HIV infected people to stop taking their ARVs to get sick so as to get their 
disability grants back. Furthermore, 51% of the sample attributed their loss of a disability grants 
to doctors deciding that they were no longer eligible. In Coetzee et al., (2011) doctors reported 
that they were sometimes threatened by patients who did not re-qualify for a grant by saying that 
they would stop taking their medication entirely. Venkataramani, Maughan-Brown, Nattrass, and 
Ruger (2009) found no statistical association between receipt of a grant and adherence. 
2.5.2.3 Cultural and political barriers. 
2.5.2.3.1 Health Literacy. Kalichman and Simbayi (2004) reported that as a result of poor 
education in resource-constrained settings many patients have a limited knowledge of health 
literacy. Health care providers in Botswana found that gaps in patients‟ knowledge about ART 
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directly impacted upon treatment, as patients were often not sure how to follow the regimen 
(Weiser et al., 2003). According to Murray et al. (2009), health literacy information is often 
provided in terms and in contexts that patients do not understand, and this leads to 
misunderstanding of the way the regimen should be followed. In accordance with Murray et al. 
(2009), Coetzee et al., (2011) reported that a low level of health literacy meant that several 
patients failed to fully understand written instructions from clinicians on how to follow the 
treatment regimen. Other studies have also found inadequate health literacy as a barrier to 
adherence (Kalichman et al., 1999; Catz et al., 2000). 
2.5.2.3.2 Stigma and disclosure. A major barrier to retention in care and pill-taking 
adherence are the difficulties patients experience in disclosing their status to others; especially to 
those within their immediate social networks (Derlega, Winstead, Greene, Serovich & Elwood, 
2002; Coetzee et al., 2011). A lack of disclosure forces patients to hide their medication which 
results in a change in their dosing schedules, and having to conceal obvious side effects (Brown 
et al., 2003). Rintamaki, Davis, Skripkauskas, Bennet and Wolf (2006), describe a conceptual 
model for understanding concerns that PLWH have around stigma. According to these authors, 
“the anxiety and fear of being stigmatized defines a person‟s concern for HIV stigma.” In their 
model, they describe various pathways through which stigma concerns (such as perceptions of 
others‟ attitudes towards HIV) might impact negatively on health. A person with a high level of 
stigma concerns would be less likely to disclose their status, out of fear or shame. An added 
complication then arises when patients are forced to take medication at inopportune times and 
more often than not, in less-than-private environments. Coetzee et al. (2011) reported that 
patients often had to seek ART at clinics outside of their communities to prevent being identified 
as HIV positive. The travel costs associated with seeking treatment further away from home 
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added to the many barriers patients face in terms of adhering to clinic visits (Weiser et al., 2003; 
Hardon et al., 2007; Coetzee et al., 2011; Kagee et al., 2010). According to Coetzee et al. (2011) 
stigma made it difficult for patients to take their medication at home especially as a lack of 
privacy due to overcrowded living conditions was the norm. In both Coetzee et al. (2011) and 
Kagee and Delport (2010) participants reported that as a result of stigma, patients reported being 
very reluctant to inform their employers of their HIV status which made it difficult to attend 
monthly clinic appointments. High unemployment rates in low income countries meant that 
several patients were reluctant to forgo a day‟s wage, even if it meant missing a scheduled clinic 
visit. According to Shisana et al., (2005) stigma and discrimination are two of the primary 
barriers to HIV prevention, treatment, and care. Furthermore, and especially within resource-
limited communities, an HIV –positive diagnosis may also serve as an instigator of violence. 
Violence, especially amongst women following an HIV-positive diagnosis, is reportedly a major 
contributing factor to the lack of disclosure to intimate partners. In their study on violence 
associated with an HIV positive diagnosis, Gielen et al., (2000) found that 13% of the women 
recruited in their sample experienced violence after disclosure to an intimate partner, and 32% 
experienced violence before and after disclosure. In their study, Gilbert and Walker (2010) 
interviewed 44 PLWH at an HIV/AIDS clinic in Johannesburg. The purpose of the interviews 
was to explore the extent to which patients on ART perceived and experienced stigma. 
Respondents indicated that stigma played a significant role throughout their illness as it was 
experienced from the early stages of getting tested, to disclosure and throughout commitment to 
ART. The fear of being identified as HIV positive prevents much needed disclosure of the illness 
(Health Resources and Services Administration [HRSA], 2003) and limits access to treatment 
(Mahajan et al., 2008). 
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2.5.2.3.3 Migration. In Coetzee et al. (2011) several nurses indicated that Xhosa-speaking 
patients often had to migrate to the Eastern Cape for family related matters. Furthermore, nurses 
reported that patients would remain in the Eastern Cape for extended periods of time, and disrupt 
the continuity of care by not having acquired the necessary transfer letters to seek treatment at 
hospitals within that region (Coetzee et al., 2011; Kagee & Delport, 2010). Swartz (1998) 
indicates that migration amongst patients who are seasonal workers often results in loss to 
follow-ups.  
2.5.2.3.4 Social discouragers. In Coetzee et al. (2011) a nurse reported that some local 
charismatic churches were a great disincentive to medication adherence. A nurse reported that 
patients were encouraged to forgo biomedical treatment and that failure to do so would signal a 
lack of faith in prayer. Studies (Coetzee et al., 2011; Kagee & Delport, 2010; Walker, Reid, & 
Cornell, 2004) have also indicated that some patients showed preference for religious or 
traditional healing beliefs over treatment.  
2.6 Theoretical Conceptualization of Structural Barriers to Adherence 
In theoretical terms, Bronfenbrenner‟s Ecological Systems Theory (Bronfenbrenner, 1975) 
may be used to conceptualize how the social context exerts an influence on individual behaviour, 
in this case adherence to ART. According to Bronfenbrenner (1975), the ecological environment 
is a “nested arrangement” where each structure is contained within another structure. These so-
called structures are named the micro-, meso-, exo- and macrosystems, where the micro-, meso, 
and exo- systems are contained within the macro-level as can be seen in the figure below. 
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Figure 1: The four systems of Bronfenbrenner Ecological Systems Theory 
The microsystem involves an individual‟s interaction with family, friends, neighbours, 
community members and the church (Bronfenbrenner, 1975). According to Coetzee et al., (2011) 
at this level, an individual is able to build social networks with others and thereby gain a valuable 
source of support which promotes a health enabling context. The term social capital has been 
used by various authors to describe the role that community cohesion may play in promoting 
health behaviour (Campbell 2001; 2003). The core elements of social capital include a sense of 
trust, reciprocity and cooperation amongst the members of a particular social network (Putnam et 
al., 1993). Together these factors are intended to positively influence the health behaviour of a 
community provided each member share the common goal of improving public health. Stigma-
Macrosystem 
Exosystem 
Mesosystem 
Microsystem 
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related barriers and the importance of disclosure in gaining social support fall on this level as 
well (Coetzee et al., 2011).  
The mesosystem involves interactions between the components of the microsystem (e.g. 
the relationship between the individual‟s home and workplace) (Bronfenbrenner, 1975). 
According to Coetzee et al., (2011), the mesosystem may be most closely associated with 
poverty-related barriers. The exosystem is the third component of the Ecological Model. This 
system involves the links between  two or more settings where one link does not contain the 
individual concerned, but the events/settings that directly influence the immediate environment 
of this person (e.g. For a parent it involves the link between the school and neighbourhood). 
According to Coetzee et al., (2011) the structural barriers patient‟s face in terms of those posed 
by the public healthcare system for example, exists on this level. 
The macrosystem contains all the other systems to embody an individual‟s beliefs 
systems, customs, and bodies of knowledge, lifestyles and opportunity structures that are 
embedded in each of the previously mentioned systems (Bronfenbrenner, 1994).  
Roura and colleagues (2009) applied a social ecological approach to understanding both 
barriers and facilitators to patients‟ ART treatment adherence. Their approach holds that 
individuals adapt their behaviour based on the social environment in which they find themselves 
and base their decisions on the information, influence, and interactions afforded to them through 
social networks, institutions and relationships. The social-ecological approach considers both the 
individual and structural factors that influence an individual‟s decision making.  
 2.7 Conclusion to Chapter 
A review of the literature has indicated that despite widespread access of ART, adherence 
to treatment remains sub-optimal. A failure to sustain the level of adherence needed for 
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successful treatment outcomes means patients risk virological failure and drug resistance. 
Treatment failure would require most patients to initiate second-line therapy which is far more 
expensive than first-line therapy. Despite a steadily emerging body of knowledge, structural 
barriers to adherence still require a greater level of understanding and research. The present 
study therefore aims to add to the literature by understanding and identifying the underlying 
factor structure of four scales assessing adherence to ART at two levels namely, adherence to 
clinic attendance and adherence to pill-taking. The next chapter will provide the methodology 
that was followed to conduct this study.  
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CHAPTER 3 
METHOD 
3.1 Research Design 
The study was a research survey with a cross-sectional design. The primary purpose of 
the study was to construct a set of scales identifying the most salient structural barriers to 
adherence to ART that PLWH experience. A secondary aim of the study was to identify the 
underlying factor structure of the four scales and thereby justify the calculation of a total score 
for each scale. 
3.2 Research Method 
3.2.1 Participants. 
A convenience sample of 291 PLWH currently receiving ART was recruited for the 
study. Patient advocates from a non-government organisation (NGO) in Somerset West assisted 
in recruiting patients from one hospital and one primary health care clinic in the Boland region. 
The self-report measures were administered in both English and Afrikaans.   
3.2.2 Scale development. 
The items included in the scale were constructed from the results of three previous 
studies (Coetzee et al.,  2011; Kagee & Delport, 2010; Nothling, 2009) aimed at identifying 
structural barriers to adherence to ART through qualitative analysis. Coetzee et al. (2011) 
conducted in-depth qualitative interviews with doctors and nurses from a primary health care 
clinic in the Boland region. The purpose of these interviews was to gain an understanding of 
health care workers‟ (HCW‟s) perspectives of the structural barriers to ART adherence that 
patients attending their clinic may face. Kagee and Delport (2010) conducted two in-depth focus 
groups as well as follow up interviews with patient advocates from an NGO in Somerset West. 
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The focus groups were aimed at understanding what PA‟s considered as the key barriers patients 
faced in attending clinic appointments and taking their medication. Nothling, (2009), conducted 
semi-structured qualitative interviews with 10 patients receiving ART from a primary healthcare 
hospital in the Western Cape. The interviews were aimed at identifying the barriers that patients 
enrolled on the national ART programme in South Africa experience. 
In all three studies, the interviews and focus group discussions were recorded and 
transcribed. The transcripts were then analysed with the assistance of Atlas.ti 4.2. Atlas.ti is a 
computer programme that assists in the analysis of qualitative data by allowing the user to code 
the data for relevant themes. The themes that emerged from that data formed the basis for the 
items that were constructed for inclusion in the scales.  
3.2.2.1 Item development. 
After the qualitative data were collected, conventional guidelines for scale development 
were used to construct the items. Careful attention was given to include items that were clear, of 
an adequate length, and were not ambiguous (De Vellis, 1991).  
 Structural barriers to adherence were conceptualized at two levels namely, barriers to 
clinic attendance as well as barriers to pill taking. The items were constructed with two sets of 
stems. The first stem used the patient him or herself as the anchoring agent, e.g. “I do not attend 
my clinic appointments because…”, and “I do not take my ART pills because…” The second 
stem asked that patients consider the barriers that other patients might face, e.g. “Patients do not 
attend their clinic appointments because…”, and “Patients do not take their ART pills 
because…” This scale construction procedure produced four separate scales for measuring 
structural barriers to adherence to ART, namely: Barriers to MY clinic attendance: SBS-1; 
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Barriers to MY medication taking: SBS-2; Barriers to PATIENTS‟ clinic attendance: SBS-3 and 
Barriers to PATIENTS‟ medication taking: SBS-4. 
On each scale patients were asked to endorse the extent to which each structural barrier 
applied to them on a Likert scale ranging from 1 to 5 (1=Never, 2= Rarely, 3=Some of the time, 
4= Most of the time and 5= Always). Reporting on other patients‟ barriers to adherence ranged 
from 1 to 4 (1= Not true for any patients, 2= True for some patients, 3= True for most patients 
and 4 = True for all patients).  
3.2.2.2 Item refinement. 
Once an initial body of items had been developed to sufficiently cover the scope of the 
underlying latent variable and the issues of redundancy, clarity and ambiguity had been 
accounted for, the items were subjected to external scrutiny.  An expert in item development 
(Professor Deon de Bruin) reviewed the relevance and quality of each item. After taking the 
recommendations into account, the necessary adjustments and or removal of items were made. 
After making these changes, I conducted a pilot study with 20 participants to assess whether 
scale items were comprehensible and at an appropriate reading level. Thus, of the original 61 
items on the four scales, 49 were retained in the final version of the scales. Three of the scales 
contain 12 items and one scale contains 13 items, yielding a total of 49 items.  
3.3 Measuring Instruments 
3.3.1 Demographic information (Addendum A). 
A self-administered questionnaire assessed demographic information such as „gender‟, 
„ethnicity‟, „age‟, „marital status‟, „current living situation‟, education level‟, „work situation‟, 
„annual family income‟, and „first language‟.  
 
Stellenbosch University  http://scholar.sun.ac.za
31 
 
3.3.2 Structural Barriers Scales 
3.3.2.1 Barriers to MY clinic attendance: SBS-1(Addendum B). The SBS-1 allows 
patients to identify the extent to which each structural barrier to clinic attendance applies to their 
own circumstances. The scale contains a total of 12 items. 
3.3.2.2. Barriers to MY medication taking: SBS-2(Addendum C). The SBS-2 allows 
patients to identify the extent to which each structural barrier to pill taking applies to their own 
circumstances, and contains 12 items. Items 041 and 042 were excluded from analyses as it did 
not make any theoretical sense to include them as they did not explain barriers to pill taking. 
3.3.2.3 Barriers to PATIENTS’ clinic attendance: SBS-3(Addendum D). The SBS-3 
contains 12 items. The scale allows patients to identify the extent to which each structural barrier 
to clinic attendance applies to other patients living with HIV and receiving ART.  
3.3.2.4 Barriers to PATIENTS’ medication taking: SBS-4(Addendum E). The SBS-4 
contains 13 items. This scale allows patients to identify the extent to which each structural 
barrier to medication taking applies to other patients living with HIV and receiving ART. Items 
071 and 072 were omitted from all analyses for the same reasons as in the SBS-2. 
3.4 Procedure 
Patients living with HIV and receiving ART were recruited by patient advocates from an 
NGO in the Western Cape. Fifteen patient advocates were approached and recruited to assist in 
data collection. The patient advocates provide psychosocial support and care to patients 
receiving ART from both a hospital and primary health care clinic in the Boland area.  
As each of the PA‟s do between 40 and 60 home-based visits to patients attending the 
hospital and clinic as mentioned above each month, it seemed a plausible way in which to recruit 
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patients and subsequently avoid the possibility of disrupting clinic visits. The researcher met 
with the patients advocates on two occasions.  
The first meeting was aimed at getting to know each of them, as well as explaining the 
nature of the study and requesting their assistance in data collection. The second meeting 
involved an in depth look at the questionnaire package to be administered to patients, as well as 
the importance of receiving written consent following an explanation of the ethical details 
concerning the study.  
Patient advocates received a set of flyers (Addendum F) from the researcher which were 
handed to patients inviting them to partake in the study. PA‟s informed patients of the following 
during home visits: (1) the nature as well as intentions of the present study, (2) the potential risks 
and benefits involved, (3) the confidentiality and anonymity associated with their participation, 
(4) that participation is voluntary and, (5) that they were allowed to stop at any point during the 
course of the investigation.  
All patients who agreed to partake in the study signed an informed consent form (see 
Addendum G), acknowledging that the aforementioned was indeed explained and understood. 
Each of the fifteen patient advocates received 20 copies of the questionnaire package to 
administer to their patients during a routine home-based or clinic visit.  
Upon completion of the self-report questionnaire package patients received a R 20.00 
grocery voucher as a token of gratitude for participation in the study. Furthermore, as a token of 
appreciation for their assistance in recruiting patients for the study, PA‟s received a R 50.00 
shopping voucher.  Ethical clearance for the following study was received from the Health 
Research Ethics Committee of the University of Stellenbosch (Addendum H), The Western Cape 
Department of Health (Addendum I) and The City of Cape Town (Addendum J). 
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3.5 Data Analysis 
All the statistical analyses conducted on the data gathered from this research were performed 
using the Statistical Package for the Social Sciences (SPSS) version 18.0. All analyses were two-
tailed and alpha (α) was set at 0.05.  
 3.5.1 Data Screening. 
After initial data-capturing, an integrity check was conducted to see if all the data had been 
entered correctly. Case summaries were calculated to determine if any data had been entered 
incorrectly (out of range values), to check for missing values and deciding how to deal with these 
values, to check for outliers and to test for normality. 
Due to the random nature of the missing data, the missing variables were left as is and no 
subsequent analysis was done to replace this data with mean or regression substitution. Listwise 
deletion of missing cases was selected for the factor analyses. Listwise deletion involves the 
removal of an entire case, should there be any missing data for a particular participant. A 
complete descriptive analysis was performed on participants‟ demographic information. 
Exploratory factor analysis (EFA) was then performed on each of the SBS scales.  
3.5.2 Statistical procedure. 
3.5.2.1 Sample size. An adequate sample size is essential to conduct a sufficient factor 
analysis. It has been suggested that as a rule of thumb there should be between 10 to 15 
participants for every variable that is included in the instrument (Field, 2005). Therefore a 
sample of 291 participants was considered sufficient to support the EFA. 
3.5.2.2 Exploratory factor analysis (EFA). Factor analysis attempts to provide an 
explanation for the correlations seen between an observed set of variables with a smaller set of 
factors. EFA was chosen as it allows for the identification of underlying factor structures without 
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any constraints as imposed by a confirmatory factor analysis (CFA). EFA is most appropriate in 
the early stages of scale development, whereas CFA is most appropriate when the factor 
structure has been established (Fabrigar, Wegener, MacCallum & Strahan, 1999).  
3.5.2.2.1 Descriptives. To determine whether the data was suitable for factor analysis the 
Kaiser-Meyer-Olkin (KMO) statistic was computed. The KMO is a ratio of squared correlations 
to squared partial correlations between variables. The value ranges between 0 and 1. A value 
close to 1 indicates “compact” patterns of correlations and therefore the analysis should yield 
reliable factors. As an additional screen for EFA, Bartlett‟s test of sphericity was computed. 
Bartlett‟s test of sphericity was used to ensure that the inter-item correlation matrix was not an 
identity matrix (Field, 2005 p. 640).   
3.5.2.2.2 Extraction. The method chosen for extraction was principal components. Only 
factors that had eigenvalues larger than 1 were extracted and retained (Kaiser 1960, 1974).  
Additionally a scree plot was requested to provide a visual representation of the number of 
factors retained based on the Kaiser specification. Only item loadings of 0.40 or greater were 
retained to reveal the primary factor each item loaded onto (Field, 2005 p. 633).  
3.5.2.2.3 Rotation. Direct oblimin was chosen as the method of rotation as it is assumed 
that the factors extracted from the analysis, based on theoretical reasoning, would be correlated 
with one another (Field, 2005). A factor correlation matrix showed significant correlations 
between the factors.  
3.5.2.3 Second order factor analysis. It was expected from the EFA that a single 
underlying variable or general factor would be identified that explained the largest proportion of 
common variance shared amongst the items. Thus the correlations that were obtained between 
the first order factor s (factors obtained from the principal-components exploratory factor 
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analysis) were used to determine the higher order or general factor by means of a Schmid-
Leiman hierarchical transformation (Schmid-Leiman, 1957). The identification of a general 
underlying factor justified the calculation of a total score (De Bruin, 2006) for each scale.  
3.5.2.4 Reliability analysis. Cronbach‟s alpha internal reliability coefficient was 
computed for each SBS scale. Although the value for an acceptable Cronbach‟s alpha coefficient 
varies amongst different authors, for this study a value > 0.8 was regarded as acceptable (Field, 
2005). The next chapter will present the results obtained from the study. 
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CHAPTER 4 
 
RESULTS 
 
 
4.1 Demographics of the Sample (Table 1) 
As can be seen in Table 1, the sample consisted of 291 participants of which 63.9% was 
female and 35.4% male. The mean age of the sample was 35 (SD= 9.05). A large proportion of the 
sample was single (69.4%) and 38.5% of the sample reported living with other adults and children.  
Most of the participants indicated that they were unemployed (59.8%), and as much as 46% of the 
sample stated they were unsure how much they earned annually before tax. Only 9.3% of the 
sample had no formal education. However, 44.3% of the sample had attended high school but did 
not complete Grade 12. The majority of participants (59.1%) reported Xhosa as their first 
language. Approximately 22% of the sample reported Afrikaans as their first language, and 3.4% 
of the sample reported English as their first language. Table 1 also shows the number of 
participants (out of 291) who completed the information for each variable, as indicated by n*. 
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Table 2  
Demographics of the sample 
 
   
n* Frequency  (%) M SD 
Age  279  
 
35.49 9.05 
Gender  289  
 
1.64 
 
 
Male 
 
103 35.4  
 
 
Female 
 
186 63.9  
 Marital status  274  
 
1.82 
 
 
single 
 
202 69.4 
  
 
widowed 
 
15 5.2 
  
 
separated 
 
8 2.7 
  
 
divorced 
 
3 1 
  
 
married or living with a 
significant other in a 
marriage -like relationship 
 
46 15.8 
  Living situation  280  
 
3.52 
 
 
Live alone 
 
62 21.3 
  
 
Live in an institution or 
retirement home 
 
9 3.1 
  
 
Live with other adults (s), no 
children 
 
42 14.4 
  
 
Live with children only 
 
55 18.9 
  
 
Live with other adults and 
children 
 
112 38.5 
  Highest level of 
education  
 
283 
  
2.4 
 
 
No formal education 
 
27 9.3 
  
 
Completed primary school 
 
122 41.9 
  
 
Attended high school but did 
not complete matric 
 
129 44.3 
  
 
Attended university, college 
or technikon but did not 
graduate 
 
4 1.4 
  
 
Graduated from university, 
college or technikon. 
 
1 0.3 
  (table continues) 
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Employment 
 
 
269 
 
 
2.63 
 
Employed full time 
 
25 8.6 
  
 
Employed part time 
 
63 21.6 
  
 
Unemployed 
 
174 59.8 
  
 
Homemaker 
 
3 1 
  
 
Disabled 
 
2 0.7 
  
 
Student 
 
2 0.7 
  Annual income before 
tax 
 
250 
  
5.55 
 
 
No income 
 
1 0.3 
  
 
less than R 12, 000 
 
73 25.1 
  
 
R 10, 0001-R 40, 000 
 
3 1 
  
 
R 80, 001-R 110, 000 
 
12 4.1 
  
 
R 240, 001 and above 
 
27 9.3 
  
 
Do not know 
 
134 46 
  First language  261   2.74 
 English  10 3.4   
 Afrikaans  65 22.3   
 Xhosa  172 59.1   
 Other  12 4.1   
  English and Afrikaans   2 0.7     
* Number of participants that completed this question 
 
4.2 Exploratory Factor Analysis (EFA) 
Principal components exploratory factor analysis was conducted on all four scales in 
order to identify the underlying factor structure of each scale. The method of rotation used in the 
EFA was direct oblimin as the assumption was that the factors were correlated with one another. 
The determinant, of the inter-correlation matrix, was used as a test for multicollinearity. Thus 
only items with inter-correlations < 0.80 were included in the EFA. After the EFA had been 
conducted on all the scales, a second order factor analysis was performed on the factor 
correlations obtained from the first order analysis. The factor solution was transformed to a 
hierarchical solution.  
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4.2.1 Barriers to MY clinic attendance: SBS-1. 
4.2.1.1 Multicollinearity (Determinant), Kaiser-Meyer-Olkin Measure of Sampling 
Adequacy (KMO) and Bartlett’s Test of Sphericity.  On the first iteration of the EFA, inspection 
of the correlation matrix (R-matrix) yielded high correlations (r>0.8) between two pairs of items. 
The high correlations (multicollinearity) between these items suggest that one of them may be 
redundant and therefore need to be removed.   Firstly, a high correlation (r=0.85) existed 
between items; “I do not attend my clinic appointments because I do not want others to see me 
receive HIV treatment” and “I do not attend my clinic appointments because I do not want to be 
identified as HIV positive”. Secondly, a high correlation (r=0.80) existed between items;  “I do 
not attend my clinic appointments because there is no place where I can speak to a nurse or 
counsellor without being heard by other people” and “I do not attend my clinic appointments 
because the nurses do not speak my language”. Consequently the items “I do not attend my clinic 
appointments because I do not want others to see me receive HIV treatment” and “I do not attend 
my clinic appointments because the nurses do not speak my language” were removed. The EFA 
was then performed again. No items in the R-matrix correlated at a level above 0.80 with each 
other. The determinant was 0.001 which was greater than 0.00001, thus indicating that 
multicollinearity was no longer a problem (Field, 2005 p. 648).  
The Kaiser-Meyer-Olkin Measure of Sampling Adequacy (KMO) value was 0.83. This 
value was close to 1.00 indicating that factor analysis (FA) was a suitable method of analysis. 
Hutcheson and Sofroniou (1999) state that KMO values between 0.50 and 0.70 are mediocre, 
between 0.70 and 0.80 are good, and values between 0.80 and 0.90 are great to indicate 
suitability for FA. Bartlett‟s Test of Sphericity was significant (p <0.01) which suggested that 
the correlation matrix was significantly different from an identity matrix indicating that the items 
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correlated with one another which made the possibility of finding factors more likely (Field, 
2005, p. 642). 
4.2.1.2 Primary factor structure. After the principal-components EFA had been 
conducted a total of three primary factors were extracted accounting for 69.17% of the total 
variance among the items. The Scree plot (Figure 2) and the eigenvalues>1 criterion (Kaiser 
1960, 1974) showed that three factors should be retained. The correlations between these factors 
then formed the input data of the second-order factor analysis. 
 
 
 
 
 
 
 
 
 
 
Figure 2. Scree plot for the SBS-1. 
4.2.1.3 Hierarchical factor structure. A second order factor analysis was performed on 
all the items included in the scale. Thus, a Schmid-Leiman hierarchical transformation (Schmid-
Leiman, 1957) was performed to identify whether the items loaded strongly onto a secondary 
order factor. As can be seen from Table 3 below the items did indeed load saliently onto a 
secondary order (general) factor. This factor was named Barriers to Clinic Attendance. Thus, 
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although three primary factors were identified, the results in Table 3 show that 63.2% of the 
variance was explained by the secondary order factor. This is proportionally much more than the 
variance explained by the primary factors. On the basis of these results it can be concluded that 
the SBS-1 can be treated as a unidimensional scale. Unidimensionality validates the calculation 
of a total score. A maximum score of 60 and a minimum score of 12 can be obtained on the SBS-
1. Thus, an overall score that exceeds 30 on this scale suggests that multiple barriers to clinic 
attendance were experienced.  The mean score for this scale was 30.84, suggesting that most 
patients who completed the scale experienced structural barriers to clinic attendance as salient.  
 
Table 3 
Factor loadings of Schmid-Leiman Solution for the SBS-1 
Item General Primary1 Primary2 Primary3 
12 0.67 -0.04 -0.63 0.07 
13 0.66 -0.03 -0.62 0.06 
14 0.68 0.18 -0.51 -0.16 
16 0.60 0.44 0.01 -0.08 
17 0.74 0.38 0.03 0.20 
18 0.73 0.22 -0.03 0.38 
19 0.63 -0.01 -0.02 0.67 
20 0.62 0.27 -0.03 0.17 
21 0.72 0.40 -0.03 0.06 
22 0.71 0.34 -0.18 -0.02 
23 0.65 0.46 0.03 -0.04 
25 0.65 0.03 -0.03 0.62 
  % Variance explained by extracted 
factors 
63.2 11.5 12.7 12.7 
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4.2.1.4 Reliability of the SBS-1. The SBS-1 showed highly satisfactory reliability (α = 
0.89). Table 4 below shows the item-by-item descriptive analyses for the scale and provides 
further evidence for the homogeneity of the scale. 
Table 4 
 
Item-by-item Descriptive Analyses for the SBS-1 
 
Item Description 
Corrected 
Item-Total 
Correlation 
(r)** 
α-iid* M SD 
12  I do not attend my clinic appointments 
because the clinic is too far from the bus 
stop/ taxi rank.      
0.55 0.88 2.6 1.52 
13  I do not attend my clinic appointments 
because transport to the clinic is too 
expensive. 
0.56 0.88 2.34 1.48 
14  I do not attend my clinic appointments 
because it takes too much time to travel to 
and from the clinic. 
0.61 0.88 2.8 1.55 
16  I do not attend my clinic appointments 
because I do not want to be identified as 
HIV positive. 
0.58 0.88 2.99 1.48 
17  I do not attend my clinic appointments 
because the staff at the clinic is rude to me. 
0.69 0.88 2.27 1.3 
18  I do not attend my clinic appointments 
because the staff at the clinic is impatient 
towards me.                                              
0.65 0.88 2.34 1.31 
19  I do not attend my clinic appointments 
because there is no privacy at the clinic 
when I meet with the nurse. 
0.49 0.89 2.59 1.49 
20  I do not attend my clinic appointments 
because I cannot get time off work to do so. 
0.56 0.88 2.19 1.33 
21  I do not attend my clinic appointments 
because I have to wait too long to see the 
doctor, nurse, or pharmacist. 
0.68 0.88 2.75 1.42 
22  I do not attend my clinic appointments 
because I feel unsafe walking to and from 
the clinic. 
0.66 0.88 2.59 1.48 
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23  I do not attend my clinic appointments 
because the clinic is too crowded. 
0.63 0.88 2.98 1.56 
25  I do not attend clinic appointments because 
there is no place where I can speak to a 
nurse or counsellor without being heard by 
other people. 
0.53 0.89 2.41 1.46 
*Cronbach‟s alpha if item deleted, **p < 0.01 
 
4.2.2 Barriers to MY medication taking: SBS-2. 
4.2.2.1 Multicollinearity (Determinant), Kaiser-Meyer-Olkin Measure of Sampling 
Adequacy (KMO) and Bartlett’s Test of Sphericity. On the first iteration of the analysis an 
inspection of the correlation matrix revealed a high correlation (r>0.80) between items “I do not 
take my ART pills because my traditional healer has told me not to” and “I do not take my ART 
pills because the church pastor has told me not to” (r = 0.82). As a result one of the items was 
removed, namely, “I do not take my ART pills because my traditional healer has told me not to”. 
The EFA was then conducted again. Inspection of the correlation matrix now showed no high 
correlations and the determinant was satisfactory (0.002) (Field, 2005). However the pattern 
matrix revealed that one item did not load onto either of the two factors extracted from the EFA. 
This item (“I have difficulty obtaining my ART pills because the clinic is often out of stock of 
pills”) was subsequently removed. The EFA was then performed again. The KMO statistic was 
0.86, which indicated that FA was a suitable analysis for the data. Bartlett‟s Test of Sphericity 
revealed that the correlation matrix was significantly different from an identity matrix (p <0.01). 
4.2.2.2 Primary factor structure. Three primary factors were extracted based on Kaiser 
(1960, 1974) criterion of eigenvalues >1. These factors, as can be seen in the Scree plot (Figure 
3), accounted for 64.03% of the total variance explained. The correlations between these factors 
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then formed part of the second-order factor analysis that was performed to identify a secondary 
order factor. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Scree plot of factors extracted for the SBS-2. 
 
4.2.2.3 Hierarchical factor structure. A second order factor analysis was performed on 
all the items included in the SBS 2. Thus, a Schmid-Leiman hierarchical transformation was 
performed to identify whether the items loaded strongly onto secondary order factor. As can be 
seen from Table 5 below, the items did indeed load saliently onto a secondary order factor. This 
factor was named Barriers to Pill Taking. Thus, although three primary factors were identified, 
the results in Table 6 show that 57.7% of the variance was explained by the secondary order 
factor. This result is proportionally much greater than the variance explained by the primary 
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factors. On the basis of these results, it may therefore be concluded that the SBS-2 can be treated 
as a unidimensional scale. Unidimensionality thus validates the calculation of a total score. A 
maximum score of 65 and a minimum score of 12 can be obtained on the SBS-2. The mean score 
for this scale was 32.39, suggesting that most patients who completed the scale experienced 
structural barriers to pill-taking as salient.  
 
Table 5 
Factor loadings of Schmid-Leiman Solution for the SBS-2 
Item General Primary1 Primary2 Primary3 
26 0.54 0.62 -0.11 -0.01 
27 0.61 0.58 -0.03 0.01 
28 0.69 0.34 0.08 0.23 
29 0.76 0.37 0.31 0.04 
30 0.64 0.08 0.40 0.14 
31 0.70 0.32 0.36 -0.01 
33 0.46 -0.12 0.62 -0.06 
34 0.76 0.19 0.41 0.12 
35 0.68 0.21 0.41 0.02 
36 0.52 -0.11 0.63 -0.01 
37 0.62 0.54 0.06 -0.03 
38 0.48 -0.15 0.06 0.56 
40 0.56 0.12 -0.08 0.50 
% Variance explained by extracted 
factors 
57.7 17.3 17.5 7.5 
 
4.2.2.4 Reliability of the SBS-2. The SBS-2 showed highly satisfactory reliability (α = 
0.87). Table 6 below shows the item-by-item descriptive analyses for the scale and provides 
further evidence for the homogeneity of the scale. 
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Table 6 
 
Item-by-item Descriptive Analyses for the SBS-2 
 
Item  Description 
Corrected 
Item-Total 
Correlation 
(r) ** 
α-iid* M SD 
26 
 I have difficulty taking my ART pills 
because I do not always have food with 
which to take them. 
0.51 0.86 3.18 1.30 
27 
 Taking my ART pills when I do not have 
food to eat makes me feel ill. 
0.57 0.86 3.40 1.37 
28 
 I do not take my pills if I have to take it 
in front of others. 
0.58 0.86 3.03 1.36 
29 
 I do not take my ART pills because I do 
not have a way to remind me to take 
them. 
0.73 0.85 2.51 1.27 
30 
 I do not take my ART pills because I do 
not want my employer to know I use 
them. 
0.56 0.86 2.56 1.43 
31 I forget to take my ART pills. 0.68 0.85 2.33 1.25 
33 
I do not take my ART pills because the 
church pastor has told me not to. 
0.43 0.87 1.73 1.21 
34 
When I drink alcohol I forget to take my 
ART pills.  
0.70 0.85 2.55 1.49 
35 
I do not take my ART pills because I do 
not have someone to remind me to do so. 
0.64 0.85 2.26 1.19 
36 
I do not take my ART pills because 
traditional healing works better for me. 
0.49 0.86 1.71 1.19 
37 
I do not take my ART pills because I 
cannot afford the food I need to eat when 
I take them. 
0.59 0.86 3.09 1.38 
38 
I do not take my ART pills in case my 
CD4 count increases and I may no longer 
qualify for a disability grant.  
0.26 0.88 1.62 1.57 
40 
I do not take my pills because I do not 
like taking them in front of my family.  
0.35 0.87 2.42 1.30 
*Cronbach‟s alpha if item deleted, **p < 0.01 
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4.2.3 Barriers to PATIENTS’ clinic attendance: SBS-3. 
 4.2.3.1 Multicollinearity (Determinant), Kaiser-Meyer-Olkin Measure of Sampling 
Adequacy (KMO) and Bartlett’s Test of Sphericity. Initial inspection of the correlation matrix 
revealed two variables that correlated highly with one another (r= 0.85). These were “Patients do 
not attend clinic appointments because they do not want others to see that they receive HIV 
treatment” and “ Patients do not attend clinic appointments because they do not want to be 
identified as HIV positive”. Consequently the item, “Patients do not attend clinic appointments 
because they do not want to be identified as HIV positive” was removed and the EFA was 
conducted again. The KMO was satisfactory at 0.88, and Bartlett‟s Test of Sphericity (p < 0.01) 
showed that the correlation matrix was significantly different from an identity matrix.  
4.2.3.2 Primary factor structure. A total of three primary factors (see figure 4) were 
extracted and retained after principal components EFA was conducted, accounting for 72.10% of 
the total variance. The correlations between these factors then formed part of the second-order 
factor analysis that was performed to identify a secondary order factor. 
4.2.3.3 Hierarchical factor structure. A second order factor analysis was performed on 
all the items included in the SBS-3. A Schmid-Leiman hierarchical transformation identified a 
secondary order factor. As can be seen from, Table 7 below the items loaded saliently onto the 
secondary order factor. This factor was named Barriers to Patients‟ Clinic Attendance. Thus, 
although three primary factors were identified, the results in Table 7 show that 64.1% of the 
variance was explained by the secondary order factor. This result was far greater than the 
variance explained by the primary factors. Based on the results obtained it can be concluded that 
the SBS-3 shows unidimensionality. Unidimensionality validates the calculation of a total score. 
A maximum score of 48 and a minimum score of 13 can be obtained on the SBS-3. The mean 
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score for this scale was 28.31, suggesting that participants considered barriers to clinic 
attendance as being salient for most other patients receiving ART. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Scree plot of factors extracted for the SBS-3. 
Table 7 
Factor loadings of Schmid-Leiman Solution for the SBS-3 
Item General Primary1 Primary2 Primary3 
43 0.59 0.02 0.73 -0.03 
44 0.54 0.09 0.73 0.05 
45 0.68 -0.09 0.51 -0.26 
47 0.72 0.26 0.15 -0.17 
48 0.70 0.56 0.10 0.06 
49 0.76 0.52 0.10 -0.01 
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50 0.67 0.50 -0.11 -0.06 
51 0.72 0.23 0.04 -0.24 
52 0.74 0.03 -0.02 -0.43 
53 0.79 0.00 0.18 -0.40 
54 0.76 0.03 -0.06 -0.46 
55 0.62 0.27 -0.15 -0.22 
% Variance explained by extracted 
factors 
64.1 11.5 15.8 8.5 
 
4.2.3.4 Reliability of the SBS-3. The SBS-3 showed highly satisfactory reliability (α = 
0.90). Table 8 below shows the item-by-item descriptive analyses for scale and provides further 
evidence for the homogeneity of the scale. 
Table 8 
 
Item-by-item Descriptive Analyses for the SBS-3 
 
Item Description 
Corrected 
Item-Total 
Correlation 
(r) ** 
α-iid* M SD 
43 
 Patients do not attend clinic appointments 
because the clinic is too far from the bus stop/ 
taxi rank.                           
.50 .89 2.16 .89 
44 
 Patients do not attend clinic appointments 
because transport to the clinic is too expensive. 
.44 .90 2.10 .93 
45 
 Patients do not attend clinic appointments 
because it takes too much time to travel to and 
from the clinic. 
.61 .89 2.47 .98 
47 
 Patients do not attend clinic appointments 
because they do not want to be identified as 
HIV positive. 
.65 .89 2.56 .88 
48 
 Patients do not attend clinic appointments 
because some staff members at the clinic are 
rude to them. 
.62 .89 2.02 .78 
49 
 Patients do not attend clinic appointments 
because some staff members at the clinic are 
impatient towards them. 
.68 .89 1.99 .81 
50 
 Patients do not attend clinic appointments 
because there is no privacy at the clinic when 
they meet with the nurse or counsellor. 
.60 .89 1.83 .85 
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51 
Patients do not attend clinic appointments 
because they cannot get time off work to do so. 
.66 .89 2.09 .84 
52 
 Patients do not attend clinic appointments 
because they have to wait too long to see the 
doctor, nurse, or pharmacist. 
.70 .89 2.19 .93 
53 
 Patients do not attend clinic appointments 
because they feel unsafe walking to the clinic. 
.74 .89 2.12 .99 
54 
 Patients do not attend clinic appointments 
because the clinic is too crowded. 
.71 .89 2.35 1.10 
55 
 Patients do not attend clinic appointments 
because the nurses do not speak their language. 
.55 .90 1.88 .90 
*Cronbach‟s alpha if item deleted, **p < 0.01 
4.2.4 Barriers to PATIENTS’ medication taking: SBS-4. 
4.2.4.1 Multicollinearity (Determinant), Kaiser-Meyer-Olkin Measure of Sampling 
Adequacy (KMO) and Bartlett’s Test of Sphericity .On the first iteration of the EFA, the 
correlation matrix showed a high correlation (r=0.85) between two items namely, “Patients do 
not take their ART pills because their traditional healers have told them not to” and “Patients do 
not take their ART pills because their church pastors have told them not to”. Subsequently the 
item “Patients do not take their ART pills because their traditional healers have told them not to” 
was removed. The EFA was performed again. The pattern matrix revealed that the item, 
“Patients have difficulty obtaining their ART pills because the clinic is often out of stock of 
pills” did not load onto either of the two factors extracted. This item was removed and the EFA 
was conducted again. The determinant was satisfactory. The KMO statistic of 0.89 showed that 
FA was a suitable analysis for the data. Bartlett‟s Test of Sphericity (p < 0.01) showed that the 
correlation matrix was significantly different from an identity matrix.  
4.2.4.2 Primary factor structure. On the basis of the Scree plot (Figure 5) two factors 
were extracted from the principal components EFA. These factors accounted for 63.23% of the 
total variance explained by the model. The correlations between these factors formed part of the 
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second-order factor analysis aimed at identifying a general underlying factor (secondary factor) 
for the scale. 
 
 
 
 
 
 
 
 
 
 
Figure 5. Scree plot of factors extracted for the SBS-4. 
4.2.4.3 Hierarchical factor structure. A second order factor analysis was performed on 
all the items included in the SBS-4. A Schmid-Leiman hierarchical transformation identified a 
higher order or general factor. As can be seen from, Table 9 below the items loaded saliently 
onto the secondary order factor. This factor was named Barriers to Patients‟ Pill Taking. Thus, 
although two primary factors were identified, the results in Table 9 show that 67.2% of the 
variance was explained by the general factor. This result was greater than the variance explained 
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by the primary factors extracted from the EFA. Based on the results it can be concluded that the 
SBS-3 is a unidimensional scale. Unidimensionality thus validates the calculation of a total 
score. A maximum score of 52 and a minimum score of 13 can be obtained on the SBS-3. The 
mean score for this scale was 30.74, suggesting that participants considered barriers to pill taking 
as salient for most other patients receiving ART. 
Table 9 
Factor loadings of Schmid-Leiman Solution for the SBS-4 
Item General Primary1 Primary2 
56 0.65 0.46 0.01 
57 0.62 0.46 -0.02 
58 0.59 0.50 -0.07 
59 0.68 0.41 0.09 
60 0.66 0.51 -0.03 
61 0.69 0.39 0.11 
63 0.67 -0.04 0.53 
64 0.58 0.47 -0.05 
65 0.70 0.31 0.20 
66 0.70 -0.03 0.54 
67 0.78 0.37 0.20 
68 0.71 0.22 0.29 
70 0.51 0.48 -0.11 
% Variance explained by extracted 
factors 
67.2 23.6 9.2 
 
 
4.2.4.4 Reliability of the SBS-4. The SBS-4 showed highly satisfactory reliability (α = 
0.91). Table 10 below shows the item-by-item descriptive analyses for scale and provides further 
evidence for the homogeneity of the scale. 
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Table 10 
 
Item-by-item Descriptive Analyses for the SBS-4 
 
*Cronbach‟s alpha if item deleted, **p < 0.01 
Item Description 
Corrected 
Item-Total 
Correlation 
(r) 
α-iid* M SD 
56 
 Patients do not take their ART pills because 
they do not always have food with which to 
take them.                
.71 .90 2.53 .90 
57 
 If patients take their ART pills when they do 
not have food to eat then they often feel ill. 
.68 .90 2.61 .94 
58 
 Patients do not take their ART pills if they 
have to take it in front of others. 
.69 .90 2.50 .77 
59 
 Patients do not take their ART pills because 
they do not have a way to remind themselves 
to take them. 
.68 .90 2.19 .73 
60 
 Patients do not take their ART pills because 
they do not want their employers to know that 
they are HIV positive. 
.74 .90 2.47 .78 
61 
 Patients do not take their ART pills because 
they forget to do so. 
.68 .90 2.18 .72 
63 
 Patients do not take their ART pills because 
the church pastors have told them not to. 
.37 .91 1.94 .81 
64 
 Patients forget to take their ART pills when 
they drink alcohol.  
.66 .90 2.62 .93 
65 
 Patients do not take their ART pills because 
they do not have someone to remind them to 
take it. 
.63 .90 2.19 .67 
66 
 Patients do not take their ART pills because 
they believe traditional healing works better 
for them. 
.40 .91 2.01 .79 
67 
 Patients do not take their ART pills because 
they cannot afford the food they need in order 
to take it. 
.75 .90 2.54 .93 
68 
 Patients do not take their ART pills in case 
their CD4 count increases and they no longer 
qualify for a disability grant. 
.58 .90 2.55 .99 
70 
 Patients do not take their ART pills because 
they do not like taking it in front of their 
families.  
.61 .90 2.41 .79 
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Table 11 
Correlations between the total scores of each scale 
Correlations 
  SBS 1 SBS 2 SBS 3 SBS 4 
SBS 1 Pearson 
Correlation 
1 .327** .305** 0.004 
Sig. (2-tailed)  0 0 0.951 
N 291 291 291 291 
SBS 2 Pearson 
Correlation 
.327
**
 1 .204** .132* 
Sig. (2-tailed) 0  0 0.024 
N 291 291 291 291 
SBS 3 Pearson 
Correlation 
.305
**
 .204
**
 1 0.056 
Sig. (2-tailed) 0 0  0.34 
N 291 291 291 291 
SBS 4 Pearson 
Correlation 
0.004 .132* 0.056 1 
Sig. (2-tailed) 0.951 0.024 0.34 
 
 
N 291 291 291 291 
**. Correlation is significant at the 0.01 level (2-tailed). 
*. Correlation is significant at the 0.05 level (2-tailed). 
 
Table 11 shows the correlations between the total scores of each scale. According to 
Field (2005) a correlation (r) of (+-) 0.1 shows a small effect, (+-) 0.3 shows a medium effect 
and (+-) 0.5 a large effect. Thus, most of the correlations seen between the scales have a small 
effect but are significant on either the 0.01 or 0.05 levels. The correlation between the SBS 1 and 
SBS 2 (r= 0.327, p <0.01) is stronger (more positive) than the other scales suggesting that 
barriers to pill-taking are somewhat related to barriers to clinic attendance. Overall, the SBS 2 
correlates significantly with all the scales.  
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4.3 Summary of Findings 
 
Four scales assessing structural barriers to adherence to ART were developed. Each of 
the four scales (SBS-1, SBS-2, SBS-3 and SBS-4) demonstrated highly satisfactory reliability 
and item-by-item descriptive statistics provided further evidence for the homogeneity of each 
scale. Each scale was subjected to first-order factor analysis (principal-components exploratory 
factor analysis) to identify the factor correlations necessary to perform a second order factor 
analysis. The second order factor analysis was aimed at identifying a single general factor that 
accounted for the majority of the common variance. The second order factor was identified by 
means of a Schmid-Leiman hierarchical transformation (Schmid-Leiman, 1957). The 
identification of a general factor for each scale indicated that the scale was unidimensional and 
thus warranted the calculation of a total score across all the items for each of the scales.  The 
total scores of each scale were correlated with one another and the significance of the 
correlations suggested that the barriers measured in each of the scales were either slightly or 
somewhat related to one another.  
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CHAPTER 5 
DISCUSSION AND CONCLUSION 
5.1 Introduction 
To my knowledge this is the first study to focus on determining the underlying factor 
structure of structural barriers to adherence to ART in terms of clinic attendance and pill-taking. 
Furthermore the incorporation of qualitative data gathered from in-depth interviews (phase 1) 
with key stakeholders (patients, healthcare workers and patient advocates) presented a unique 
platform on which to build on the limited literature in this area.  
A review of the literature revealed that no valid and reliable measure of structural barriers 
to adherence exists. Therefore, the main objective of this thesis was to construct a scale to 
determine the extent to which ART users experience such barriers as salient and to determine the 
factor structure for each measure. Consequently, four scales measuring structural barriers to 
adherence were constructed. The scales were designed to document the salience of the various 
structural barriers that patients experience when attending clinic appointments and taking their 
ART pills. The study also sought to identify the barriers that respondents believed other patients 
to be facing in the same regard.  
The results indicated that all four scales, SBS 1 to 4, have good reliability with alpha 
coefficients ranging from 0.87 to 0.91. Thus the items included in each of the scales 
demonstrated excellent internal consistency. After principal-components exploratory factor 
analysis was performed on each scale it appeared that a factor solution of three for the SBS-1, 
three for the SBS-2, three for the SBS-3, and two for the SBS-4 provided the best overall fit for 
the items included in the scales.  However, after a second order factor analysis was also 
performed on each of the scales by means of a Schmid-Leiman hierarchical transformation 
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(Schmid-Leiman, 1957), it was clear that the responses to the items included in each of the scales 
were dominated by secondary order or general factors. For each of the four scales the extraction 
of a secondary order factor provided a better overall fit for the items that were included. Thus, 
each of the structural barriers scales (SBS-1 to 4) demonstrated unidimensionality. 
Unidimensionality of a scale suggests the presence of a single higher-order factor driving the 
performance of the items on the scale, which in turn justifies the calculation of a total score for 
each of the scales (De Bruin, 2006).   
5.2 Factor structure of the SBS-1: Barriers to MY clinic attendance 
 5.2.1 Barriers to Clinic Attendance. A total of 12 items loaded strongly onto the factor, 
Barriers to clinic attendance. Three of these items relate strongly to the transport difficulties 
experienced by patients when attending their clinic appointments. The remainder of the items 
relate to the patients‟ experiences at the clinic itself. These clinic experiences were in relation to 
the patient-provider relationship, waiting times and overcrowding at the clinics, as well as a fear 
of being identified as HIV positive by others. The barriers to clinic attendance measured by the 
scale are those that patients typically have little control over, such as waiting times at the clinic, 
overcrowding, transport difficulties and stigma. Therefore, patients who succeed in attending 
clinic appointments are highly motivated to negotiate and overcome these barriers despite the 
expected struggle.  
Considering social-ecological theory (Roura et al., 2009) and the emergence of a general 
factor (Barriers to clinic attendance) from the results of the study, patients‟ decision-making 
process may be summarised as being based on negotiating and seeking to overcome the 
constraints of their social environment. 
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Mean descriptive statistics of each of the items (as can be seen from Table 4) that 
constitute the general factor indicate that items 14; “I do not attend my clinic appointments 
because it takes too much time to travel to and from the clinic”, 16; “I do not attend my clinic 
appointments because I do not want to be identified as HIV positive” and 23; “I do not attend my 
clinic appointments because the clinic is too crowded” were highly endorsed by most patients. 
The high scores on these items suggest that these barriers to clinic attendance were especially 
difficult for most patients to overcome. Item 14 stated, “I do not attend my clinic appointments 
because it takes too much time to travel to and from the clinic”. Various studies have cited 
travelling long distances as a barrier to clinic attendance (Weiser et al., 2003; Jaffar et al., 2005; 
Miles et al., 2007; Maskew et al., 2007; Posse et al., 2008; Coetzee et al., 2011.). In the context 
of poverty, most of the participants involved in this study were continually faced with resource 
constrained environments that consist of inadequate roads, a lack of sufficient public transport 
and under resourced public facilities such as public hospitals. Together the influences of these 
factors potentially shape the behaviour of many patients by ultimately inhibiting health 
promoting behaviour, such as adherence to clinic attendance and pill-taking. In the case of the 
participants involved in this study, many live in informal settlements and lack necessary 
commodities such as transport and access to health care. Many of the participants in this study 
may be viewed as members of communities with relatively low social capital (Campbell, 2001; 
2003) and thus lack the community cohesion needed to influence behaviour change amongst 
those who are unable to adhere to clinic appointments as a direct result of structural factors. 
Campbell (2003) argues that without sufficient social capital amongst members in a community, 
any interventions introduced to promote health-behaviours will ultimately fail.  
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Item 16 stated, “I do not attend my clinic appointments because I do not want to be 
identified as HIV positive.” It is evident that patients perceive that clinic attendance might put 
them at risk of being identified as HIV positive. Rintamaki et al‟s., (2006) model of stigma 
concerns, argues that perceptions of others‟ attitudes towards HIV may produce anxiety that one 
might reveal their status to others. Such situations then create dilemma‟s in which the importance 
of adherence to clinic attendance is weighed against others potentially learning about their status.   
Rintamaki et al‟s., (2006) model fits in well with current literature. Coetzee et al., (2011) 
reported that several patients in their sample stated that they sought health services for HIV 
outside of their home environments out of fear of being identified as living with the virus. In 
their study on perceived HIV-related stigma and disclosure following an HIV positive diagnosis, 
Derlega et al. (2002) found that persons with an HIV diagnosis feared being identified as such as 
they believed that it would lead to rejection by community members, self-blame and would risk 
the security of family members or partners.  
Item 23 stated, “I do not attend my clinic appointments because the clinic is too 
crowded.” The numbers of patients seeking ART at public health care clinics has increased 
dramatically since the national rollout in 2004. With the large numbers of patients presenting for 
ART at public healthcare facilities (Dorrington et al., 2006; UNGASS, 2010), patients are not 
only forced to spend whole days at the clinics in uncomfortable settings, but have to settle for 
minimal time with clinicians. They may therefore not find it easy to communicate deeper levels 
issues that may serve as barriers to adherence (Coetzee et al., 2011, Kagee et al., 2010).  
Extraction of the three primary factors could provide insight as to how the SBS-1 may be 
improved. Further research might be useful to ascertain conceptual clarity of each of the items so 
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that there may be no overlap in content. Overall the SBS-1 items appear to be a useful indicator 
of patients‟ subjective experience of barriers to clinic attendance.  
5.3 Factor structure of the SBS-2: Barriers to MY pill taking 
 5.3.1 Barriers to Pill Taking. Thirteen items loaded strongly onto the factor Barriers to 
Pill Taking. The items covered a wide range of barriers to pill taking that patients experience 
such as, requiring the necessary foods with which to take the pills, having no access to remainder 
tools, having trouble taking the pills in front of others, being discouraged by church pastors, and 
having a preference for alternative healing.  
 As with the previous scale, decisions to either adhere to or forgo pill-taking may be 
based on a multitude of factors such as personal experience, information available to a patient, 
the experience of others and beliefs they may have about the effectiveness and effects of the 
medication itself (Remien et al., 2003). According to Remien et al. (2003) pill taking behaviour 
is affected by emotional, behavioural, and cognitive factors. Importantly, the authors note that 
pill-taking behaviour is not a one-dimensional or static behaviour. Therefore, depending on the 
circumstances in which an individual finds him/herself, adherence at one point in a patient‟s life 
may differ from adherence at another point in his or her life. Participants in this study were not 
given a time frame on which to base their behaviour, for example, asking them to base their 
scores on how structural barriers may have influenced their pill taking behaviour in the last 
month. By adding this dimension to the each of the scales future researchers may derive a clearer 
picture of whether the barriers are general or specific to circumstance.  
As with the SBS-1, some items from the SBS-2 were endorsed more strongly by most 
patients. Means of descriptive statistics of the items (as can be seen from Table 6) showed that 
items, 26; “I have difficulty taking my ART pills because I do not always have food with which 
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to take them, 27; “Taking my ART pills when I do not have food to eat makes me feel ill”, 28; “I 
do not take my pills if I have to take it in front of others” and 37; “I do not take my ART pills 
because I cannot afford the food I need to eat when I take them” were more strongly endorsed by 
patients in relation to the other items.  
Items 26 and 27 relate to food insecurity. Food insecurity is a major consequence of 
poverty, and thus a defining feature of resource-constrained environments (Tomlinson et al., 
2010; Weiser et al., 2010). For persons living in resource-constrained environments there are 
various challenges to food security that acts as barriers to health. Persons living in poorer regions 
may have very little access to food, and when coupled with socio-economic inequality, increase 
vulnerability to HIV risk. According to Gillepsie and Drimie (2008), socio-economic inequality 
rather than absolute poverty is more closely associated with increased HIV risk. Lack of proper 
food and nutrition for persons receiving ART can render them more susceptible to AIDS-related 
illnesses and opportunistic infections (WHO, 2010). In a study conducted by Ivers et al. (2010), 
when assessed at six and twelve month intervals, patients enrolled on an HIV-program at a clinic 
in Haiti who had access to food showed improved adherence to clinic appointments and an 
increase in their body mass index (BMI). ARV‟s are known to reduce nutrient absorption and 
therefore require intake of foods rich in nutritional value. However, patients living in resource-
limited settings may not often have the finances to acquire even basic foods. Foods necessary for 
the treatment regimen may be even less likely to obtain.  
As shown in the study conducted by Weiser et al. (2010), persons living with HIV in their 
study considered skipping doses or not commencing on treatment at all if they were not able to 
afford the food necessary for desired treatment outcomes. Side effects that are experienced from 
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ARV consumption may be better managed by the consumption of the necessary foods (USAID, 
2005). Item 28 stated, “I do not take my pills if I have to take it in front of others.” 
It is evident that patients experienced an immense fear of being identified as HIV 
positive. Also worthy to note are those items not endorsed highly by participants. The item, “I do 
not take my ART pills in case my CD4 count increases and I may no longer qualify for a 
disability grant” had the lowest mean (M=1.62) of all the items. On closer examination, I 
reasoned that the item was double-barrelled in nature which meant that patients may not have 
understood how to answer this item. Future research might be focused on conceptual clarity of 
the items included in each scale.  
5.4 Factor structure of the SBS-3: Barriers to PATIENTS’ Clinic Attendance 
 5.4.1 Barriers to Patients’ Clinic Attendance. Twelve items loaded saliently onto the 
factor Barriers to Patients‟ Clinic Attendance. The items assess the same barriers to clinic 
attendance as the SBS-1. However instead of reporting on themselves, patients were asked to 
indicate the extent to which other patients experienced barriers to clinic attendance. Mean 
descriptive statistics as can be seen in Table 8, shows that  item 47 “Patients do not attend clinic 
appointments because they do not want to be identified as HIV positive”,  had the highest mean 
score (M=2.56) of all the items. As previously discussed, the effect of stigma on the lives of 
persons living with HIV is still vastly prominent in South Africa and has received much 
attention. Item 45, “Patients do not attend clinic appointments because it takes too much time to 
travel to and from the clinic” had a mean of 2.47 and was the second highest endorsed item on 
the scale. Both items 47 and 45 correspond to items 14 and 16 on the SBS-1. These items were 
similarly endorsed on both scales and thus the previous discussion accounts for this scale as well. 
Overall the SBS-3 proved a reliable measure for allowing patients to assess the barriers to clinic 
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attendance that other patients may face. On average however, participants scored patients‟ 
barriers to clinic attendance lower than they scored their own.  
5.5 Factor structure of the SBS-4: Barriers to PATIENTS’ pill taking 
 5.5.1 Barriers to Patients’ Pill Taking. Thirteen items loaded saliently onto the factor 
Barriers to Patients Pill Taking. The items assess the same barriers to pill taking as the SBS-2. 
However instead of reporting on themselves, patients were asked to indicate the extent to which 
other patients experienced barriers to pill taking. Mean descriptive statistics as can be seen by 
Table 10 show that items 64 and 68 were highly endorsed by most patients. Item 68 states, 
“Patients do not take their ART pills in case their CD4 count increases and they no longer 
qualify for a disability grant” and had a M=2.55.  
 In South Africa, patients who are too young, too old or too sick (CD count < 200 
cells/mm3) to work are eligible for a disability grant (Nattrass, 2006a) worth R 1010 per month 
(SASSA, 2010). Once deemed capable of working, patients no longer qualify for this grant. 
Given the high unemployment rates, the possibility of trading off one‟s health to re-qualify for 
the grant may become an option for some (Nattrass, 2006b). However, in follow-up studies on 
trading off health for a disability grant, Venkataramani, Maughan-Brown, Nattrass, and Ruger 
(2009) found no statistical association between receipt of a grant and adherence.  
Venkataramani et al., (2009) conducted a study in Khayelitsha (a township in Cape 
Town) where they examined the importance of the disability grant and the impact of losing it on 
patients receiving ART. Loss of the disability grant meant that many patients suffered a huge 
loss in income. However, there was no evidence of patients choosing to forgo their treatment 
over the loss of the grant. In Coetzee et al., (2011) doctors reported that their patients would 
threaten to forgo treatment if the disability grant was not renewed despite being capable of work. 
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Evidently there is still much debate surrounding disability grants as a disincentive to adherence, 
and future research should be focused on clearing this discrepancy. Item 64 stated, “Patients 
forget to take their ART pills when they drink alcohol.” The influence of substance abuse on 
ART has been cited throughout the literature as an individual barrier to adherence (Palepu et al., 
2004; Sanjobo et al., 2008; Dahab et al., 2008; Kip et al., 2009) rather than a structural barrier to 
adherence. However, Coetzee et al., (2011) refer to the lack of substance abuse treatment 
programs for PLWH in resource-constrained settings as a structural barrier to adherence.  
Overall the SBS-4 proved to be a reliable measure of barriers to pill taking. However, on 
average patients scored other patients‟ barriers to pill taking lower than they scored their own. 
5.6 Conclusion 
In this study four reliable scales assessing structural barriers to adherence to ART were 
constructed. The underlying factor structure of each of the scales was derived at by means of 
exploratory factor analysis. A general factor for each scale emerged after second order factor 
analysis had been performed. A general factor emerged for each scale because patients may have 
considered the extent of the influence of each structural barrier on either clinic attendance or pill 
taking as equally salient. However, there were certain items that individually posed a greater 
threat to adherence. Despite fairly satisfying results from the study there is still room for 
improvement on each of the scales which requires further research and application. These are 
discussion below.  
5.7 Limitations of the study 
The study should be considered in light of its many limitations.  
Firstly, due to financial constraints the measure was not translated into a Xhosa version. 
Considering that the majority of the participants indicated Xhosa as their first language, the study 
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may have been limited by not having the translated version available to them.  Secondly, patient 
advocates were asked to assist in recruitment of patients. This method of sampling may have 
resulted in not gaining access to those patients who are more serious defaulters, and perhaps 
identify more closely with the structural barriers indicated on the scales. Future research might 
expand further on the population from which the sample was recruited.  
Thirdly, the number of items in each of the questionnaire packages may have led to 
responder fatigue, and may thus have contributed to incomplete questionnaires. The number of 
variables may also have led to the response bias (circling one‟s throughout) evident in some of 
the questionnaire packages. Lastly, as patient advocates assisted patients in completion of the 
instruments the results may have been confounded by social desirability and demand 
characteristics. 
5.8 Implications for future research 
Future research might be aimed at refining the items of each scale and focus on the 
conceptual clarity of each. Item refinement may be focused on ensuring that no item is double-
barrelled. The scales might also function more accurately if a time frame be put into place, i.e. 
asking respondents to answer items based on how salient they might have been in the past week, 
or past month. Furthermore, as there is yet to be a gold standard for measuring adherence by self-
report, researchers may consider focusing attention on understanding every dimension of non-
adherence as well as possible. The results of this study have indicated that intervention research 
may help illuminate ways of helping patient‟s problem-solve and thereby negotiate the most 
salient barriers. The development, refinement and implementation of such an intervention may 
potentially rest on the data yielded by the present study. 
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Addendum A: Demographic information 
RESEARCH STUDY ON BARRIERS TO ADHERENCE TO ANTIRETROVIRAL 
TREATMENT 
Thank you for agreeing to participate in this study. You have been asked to participate in this study 
because you are receiving antiretroviral treatment for HIV.  
If you are not receiving medicine for HIV, please do not proceed with this questionnaire. 
You are free to refuse to participate in this study or to stop answering this questionnaire at any time.  
All of the information you provide us will remain confidential. No one will have access to the data except 
for the Stellenbosch research staff. No one else will see your responses to the questions.  
All data will be kept in a locked cabinet at the University of Stellenbosch.  If the data are used in any 
publications, you will not be identified by name.  
Where necessary: Please mark your answer with an X 
001_age Please write your age here:   
  
002_birth What is your date of birth:   
  
003_gende
r 
What is your gender?   Male Female 
004_mstat
us 
 What is your current 
marital status? 
Single Widowed 
  
Separated Divorced 
  
Married or living with a 
significant  
other in a marriage-like 
relationship 
 
    
005_living 
What is your current living 
situation? 
Live alone 
Live in an institution 
or 
 retirement home 
  
Live with other adults(s), no 
children 
Live with children 
only 
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Live with other adults and 
children  
006_edu 
 Please select the highest 
level  
of education that you have 
completed: 
No formal education 
Completed primary 
school 
  
Attended high school  
but did not complete matric. 
Attended university, 
college or  
technikon but did 
not graduate 
  
Graduated from university,  
college or technikon.  
007_work 
What is your current work 
situation? 
Employed full time Employed part time 
  
Unemployed Homemaker 
  
Disabled Student 
  
Retired 
 
008_inco
me 
 Which of the following 
best describes your 
approximate 
 annual family income from 
all sources, before taxes?  
Less than R12,000 R110,001-R170,000 
  
R10,001-R40,000 R170,001-R240,000 
  
R40,000-R80,000 R240,001 and above 
  
R80,001-R110,000 Do not know 
009_pob 
Where were you born 
(Town/ City)?     
010_lang What is your first language?  
  
011_other 
Which other languages do 
you speak?    
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Navorsing Studie 
Dankie dat u ingestem het om deel te neem aan hierdie studie.  Jy is gevra om deel te neem aan 
hierdie studie omdat jy anti-retrovirale behandeling ontvang vir MIV.  
 As jy nie medisyne vir MIV ontvang nie, moenie hierdie vraelys voltooi nie.  
 Jy mag weier om deel te neem aan hierdie studie of om te stop met die beantwoording van 
hierdie vraelys om enige tyd.  
 Al die inligting wat u verskaf sal vertroulik bly.  Niemand behalwe die studie leier van 
Stellenbos sal toegang he tot die inligting,. Niemand anders sal  jou antwoorde op die vrae sien 
nie.  
 Alle inligting sal gehou word in 'n geslote kas by die Universiteit van Stellenbosch. As die data 
in enige publikasies gebruik word,  sal jy nie per naam geïdentifiseer wees nie.  
Waar nodig: Merk asseblief u antwoord met 'n X 
Skryf asseblief jou ouderdom 
hier: 
  Wat is jou geboorte datum: 
  Wat is jou geslag?  Man  Vrou 
Wat is jou huidige 
huwelikstatus?  
 Enkel  Weduwee/Wewenaar 
 
 Vervreem Geskei  
 
Getroud of leef saam met 'n 
belangrike 
 ander in' n huwelik-soort 
verhouding 
 
   Wat is jou huidige verblyfs 
omstandighede? 
Leef alleen Lewe in 'n inrigting of aftree 
huis 
 
Woon saam met ander 
 volwassenes (s), geen kinders 
Lewe  met slegs kinders  
 
  
 
Woon saam met ander 
volwassenes en kinders 
   Kies die hoogste vlak van 
 opleiding wat u voltooi het: 
Geen formele onderwys Primêre skool voltooi 
 
 Hoërskool bygewoon, maar  
het nog nie matriek voltooi nie. 
 Universiteit, kollege of 
technikon 
 bygewoon, maar nie graad 
gevang nie.  
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Gegradueer aan die  
universiteit, kollege of 
technikon. 
 Wat is jou huidige werk 
situasie? 
Voltydse diens  Deeltyds in diens  
 
Werkloos  Tuisteskepper  
 
 Gestremd Student 
 
Afgetree 
 Watter van die volgende  
beskryf die beste jou 
benaderde jaarlikse 
familie inkomste uit alle 
bronne, voor belasting? Minder as R12, 000 
R110,001-R170,000 R110 
,001-R170, 000 
 
R10,001-R40,000 R10 ,001-
R40, 000 
R170,001-R240,000 R170 
,001-R240, 000 
 
R40,000-R80,000 R40 ,000-
R80, 000 
R240,001 en bo 
 
R80,001-R110,000 R80 ,001-
R110, 000 
 Weet nie 
Waar is jy gebore (dorp / 
stad)? 
  Wat is jou eerste taal? 
  Watter ander tale kan jy praat? 
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Addendum B: Barriers to MY clinic attendance: SBS-1 
Below is a list of statements that reflect some reasons why you MAY NOT ATTEND CLINIC 
APPOINTMENTS. Please circle the number that best applies to your circumstances.  
Please circle or mark one number per line to indicate your response. 
    Never Rarely 
Some 
of  
the 
time 
Most of  
the 
time Always 
  
          
012_taxi 
I do not attend my clinic 
appointments because  
the clinic is too far from the bus 
stop/ taxi rank. 1 2 3 4 5 
013_expensive 
I do not attend my clinic 
appointments because  
transport to the clinic is too 
expensive. 1 2 3 4 5 
014_traveltime 
I do not attend my clinic 
appointments because  
it takes too much time to travel to 
and from the clinic. 1 2 3 4 5 
016_stigma2 
I do not attend my clinic 
appointments because  
I do not want to be identified as 
HIV positive. 1 2 3 4 5 
017_rudestaff 
I do not attend my clinic 
appointments because  
the staff at the clinic is rude to me. 1 2 3 4 5 
018_impatient 
I do not attend my clinic 
appointments because  
the staff at the clinic is impatient 
towards me. 1 2 3 4 5 
019_privacy 
I do not attend my clinic 
appointments because  
there is no privacy at the clinic 
when I meet with the nurse. 1 2 3 4 5 
020_worktime 
I do not attend my clinic 
appointments because  
I cannot get time off work to do so. 1 2 3 4 5 
021_HCWtime 
I do not attend my clinic 
appointments because  
I have to wait too long to see the 1 2 3 4 5 
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doctor, nurse, or pharmacist. 
022_unsafe 
I do not attend my clinic 
appointments because  
I feel unsafe walking to and from 
the clinic. 1 2 3 4 5 
023_crowded 
I do not attend my clinic 
appointments because  
the clinic is too crowded. 1 2 3 4 5 
025_privacy2 
I do not attend clinic appointments 
because  
there is no place where I can speak 
to a nurse or counsellor without 
being heard by other people. 1 2 3 4 5 
 
Hier volg 'n lys van stellings wat n paar redes stel waarom jy dalk NIE JOU KLINIEK 
AFSPRAKE bywoon nie. Omkring die nommer wat die beste by jou omstandighede van 
toepassing is.  
Plaas 'n sirkel of merk een getal per lyn om jou antwoord aan te dui. 
  
Nooit Selde 
Sommige 
van  
die tyd 
Die 
meeste 
 van 
die tyd 
Altyd 
  
     
012_taxi 
Ek woon nie my kliniek afsprake 
na nie,  
omdat die kliniek te ver van die 
bus stop / taxi-staanplek is. 
1 2 3 4 5 
013_expensive 
Ek  woon nie my kliniek afsprake 
na nie, 
omdat die vervoer na die kliniek  
te duur is.  
1 2 3 4 5 
014_traveltime 
Ek woon nie my kliniek afsprake 
na nie, 
omdat dit te veel tyd vat om te reis 
na en van die kliniek af.  
1 2 3 4 5 
016_stigma2 
Ek woon nie my kliniek afsprake 
na nie,  
want ek wil nie geïdentifiseer 
word as MIV-positief is.  
1 2 3 4 5 
017_rudestaff 
Ek woon nie my kliniek afsprake 
na nie,  1 2 3 4 5 
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omdat die personeel by die kliniek 
onbeskof is met my.  
018_impatient 
Ek woon nie my kliniek afsprake 
na nie,  
omdat die personeel by die kliniek  
ongeduldig is teenoor my.  
1 2 3 4 5 
019_privacy Ek woon nie my kliniek afsprake 
na nie,  
omdat daar geen privaatheid is as 
ek deur die verpleegpersoneel 
behandel word nie 
1 2 3 4 5 
020_worktime 
Ek woon nie my kliniek afsprake 
na nie,  
omdat ek nie tyd kan afkry by die 
werk nie. 
1 2 3 4 5 
021_HCWtime 
Ek woon nie my kliniek afsprake 
na nie  
omdat die wagperiodesom die 
dokter, verpleegster of apteker te 
sien te lank is. 
1 2 3 4 5 
022_unsafe 
Ek woon nie my kliniek afsprake 
na nie   
omdat ek onveilig voel om na en 
van die kliniek af te stap.   
1 2 3 4 5 
023_crowded 
Ek woon nie my kliniek afsprake 
na nie,  
omdat die kliniek oorvol is.  
1 2 3 4 5 
025_privacy2 
Ek woon nie my kliniek afsprake 
na nie,  
want daar is geen plek waar ek kan 
praat met 'n verpleegster  
of berader sonder om deur ander 
mense gehoor te word nie.  
1 2 3 4 5 
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Addendum C: Barriers to MY medication taking: SBS-2 
Below is a list of statements that reflect some reasons why you MAY NOT TAKE YOUR 
MEDICATION in the way you are required to: 
Please circle or mark one number per line to indicate your response. 
    Never Rarely 
Some 
of  
the 
time 
Most 
of  
the 
time Always 
  
          
026_food 
I have difficulty taking my ART 
pills because  
I do not always have food with 
which to take them. 1 2 3 4 5 
027_food2 
Taking my ART pills when I  
do not have food to eat makes me 
feel ill. 1 2 3 4 5 
028_stigma3 
I do not take my pills if  
I have to take it in front of others. 1 2 3 4 5 
029_remind 
I do not take my ART pills 
because  
I do not have a way to remind me 
to take them. 1 2 3 4 5 
030_employer 
I do not take my ART pills 
because 
I do not want my employer to 
know I use them. 1 2 3 4 5 
031_forget I forget to take my ART pills. 1 2 3 4 5 
032_t.healer 
I do not take my ART pills 
because  
my traditional healer has told me 
not to. 1 2 3 4 5 
033_church 
I do not take my ART pills 
because  
the church pastor has told me not 
to. 1 2 3 4 5 
034_alcohol 
When I drink alcohol I forget to 
take my ART pills.  1 2 3 4 5 
035_remind2 
I do not take my ART pills 
because 
 I do not have someone to remind 
me to do so. 1 2 3 4 5 
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037_food3 
I do not take my ART pills 
because 
 I cannot afford the food I need to 
eat when I take them. 1 2 3 4 5 
038_diabilityg
rant 
I do not take my ART pills in case 
my CD4 count increases and  
I may no longer qualify for a 
disability grant.  
Please tick this block if you do not 
receive a disability grant. 1 2 3 4 5 
040_stigma4 
I do not take my pills because  
I do not like taking them in front 
of my family.  1 2 3 4 5 
 
Hier volg 'n lys van stellings wat n paar redes stel waarom jy NIE  JOU MEDIKASIE  in die 
manier waarop jy verplig is neem nie: Plaas 'n sirkel of merk een getal per lyn jou antwoord 
aan te dui. 
  
Nooit Selde 
Sommi
ge van  
die tyd 
Die 
meeste  
van die 
tyd Altyd 
       
026_foo
d 
Ek ondervind dit moeilik om my ART 
pille te neem omdat ek nie altyd kos het 
om saam met dit te neem nie.  1 2 3 4 5 
027_foo
d2 
As ek my ART pille neem as ek nie kos 
het om tee et nie, voel ek siek.  1 2 3 4 5 
028_stig
ma3 
 Ek neem nie my pille as ek dit voor ander 
moet neem nie.  1 2 3 4 5 
029_re
mind 
Ek neem nie my ART pille nie, omdat ek  
nie a manier het om my daaraan te 
herinner nie.  1 2 3 4 5 
030_em
ployer 
Ek neem nie my ART pille nie, want ek 
wil nie he my  werkgewer moet weet dat 
ek dit gebruik nie.  1 2 3 4 5 
031_for
get 
Ek vergeet om pille te neem ART my.  
1 2 3 4 5 
033_chu
rch 
Ek neem nie my ART pille nie, omdat die 
kerk pastoor vir my gesê het om dit nie te 
gebruik nie.  1 2 3 4 5 
034_alc
ohol 
As ek alkohol drink vergeet ek om my 
ART pille te neem.  1 2 3 4 5 
035_re  Ek neem nie my ART pille nie, omdat ek 1 2 3 4 5 
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mind2 nie iemand het om  my daaraan te 
herinner nie.  
036_t.he
aler2 
 Ek neem nie my ART pille nie, omdat 
my tradisionele genesing vir my beter 
werk.  1 2 3 4 5 
037_foo
d3 
Ek neem nie my ART pille nie, omdat ek 
nie die voedsel kan bekostig om te eet 
voor ek my medikasie neem nie 1 2 3 4 5 
038_dia
bilitygra
nt 
Ek neem nie my ART pille nie in die 
geval as my CD4 verhoog is ek nie langer 
kan kwalifiseer vir die ongeskiktheids-
toelaag nie. 
Dui asseblief in hierdie blokkie aan as jy 
nie' n ongeskiktheids-toelaag ontvang nie.  1 2 3 4 5 
040_stig
ma4 
Ek ondervind dit moelik om my ART 
medikasie te neem, omdat ek nie daarvan 
hou om dit voor my familie te gebruik 
nie. 1 2 3 4 5 
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Addendum D: Barriers to PATIENTS’ clinic attendance: SBS-3 
Below are some reasons that OTHER patients MAY NOT ATTEND THEIR CLINIC 
APPOINTMENTS. Please indicate to what extent YOU THINK these statements are true for 
people receiving medicines for HIV. Please circle or mark one number per line to indicate your 
response. 
 
  
Not true  
for any 
patients 
True 
for  
some 
patients 
True 
for  
most 
patients 
True 
for  
all 
patients 
            
043_busstop 
Patients do not attend clinic 
appointments because  
the clinic is too far from the bus 
stop/ taxi rank. 
1 2 3 4 
044_transportexp 
Patients do not attend clinic 
appointments because 
 transport to the clinic is too 
expensive. 
1 2 3 4 
045_travelclinic 
Patients do not attend clinic 
appointments because 
 it takes too much time to travel 
to and from the clinic. 
1 2 3 4 
046_stigma5 
Patients do not attend clinic 
appointments because  
they do not want others to see 
that they receive HIV treatment. 
1 2 3 4 
048_rude 
Patients do not attend clinic 
appointments because  
some staff members at the clinic 
are rude to them. 
1 2 3 4 
049_impatientstaff 
Patients do not attend clinic 
appointments because  
some staff members at the clinic 
are impatient towards them. 
1 2 3 4 
050_clinicprivacy 
Patients do not attend clinic 
appointments because  
there is no privacy at the clinic 
when they meet with the nurse 
or counsellor. 
1 2 3 4 
051_getoffwork 
Patients do not attend clinic 
appointments because  
they cannot get time off work to 
1 2 3 4 
Stellenbosch University  http://scholar.sun.ac.za
95 
 
do so. 
052_HCWtime 
Patients do not attend clinic 
appointments because  
they have to wait too long to see 
the doctor, nurse, or pharmacist. 
1 2 3 4 
053_unsafetowalk 
Patients do not attend clinic 
appointments because  
they feel unsafe walking to the 
clinic. 
1 2 3 4 
054_crowdedclinic 
Patients do not attend clinic 
appointments because  
the clinic is too crowded. 
1 2 3 4 
055_speaklang 
Patients do not attend clinic 
appointments because  
the nurses do not speak their 
language. 
1 2 3 4 
 
Hier is 'n paar redes waarom ANDER pasiënte NIE TEENWOORDIG BY HUL KLINIEK 
AFSPRAKE IS NIE.Dui asseblief aan in watter mate dink jy dat hierdie stellings  waar is vir die 
mense wat medisyne vir MIV ontvang.Plaas 'n sirkel of merk een getal per lyn aan om jou 
antwoord aan te dui. 
  
Nie 
waar vir  
enige 
pasiënte
nie 
Waar 
vir 
sommi
ge 
pasiënt
e 
Geld 
vir die  
meeste 
pasiënt
e 
Geld vir  
alle 
pasiënte 
043_bus
stop 
Pasiënte woon nie hul kliniek afsprake na 
nie, omdat die kliniek te ver is van die bus 
stop / taxi-staanplek. 1 2 3 4 
044_tra
nsportex
p 
Pasiënte woon nie hul kliniek afsprake na 
nie, omdat die vervoer na die kliniek te 
duur is. 1 2 3 4 
045_tra
velclinic 
Pasiënte woon nie hul kliniek afsprake na 
nie, omdat dit te veel tyd vat om te reis na 
en van die kliniek af. 1 2 3 4 
046_stig
ma5 
Pasiënte woon nie hul kliniek afsprake na 
nie, omdat hulle  nie wil he ander moet 
sien as hulle MIV-behandeling kry nie. 1 2 3 4 
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047_stig
ma6 
Pasiënte woon nie hul kliniek afsprake na 
nie, want hulle wil nie geïdentifiseer word 
as MIV-positief is. 1 2 3 4 
048_rud
e 
Pasiënte woon nie hul kliniek afsprake na 
nie, omdat die personeel by die kliniek 
onbeskof is met hulle. 1 2 3 4 
049_im
patientst
aff 
Pasiënte woon nie hul kliniek afsprake na 
nie, omdat die personeel by die kliniek  
ongeduldig is teenoor hulle. 1 2 3 4 
050_clin
icprivac
y 
Pasiënte woon nie hul kliniek afsprake na 
nie, omdat daar geen privaatheid is as 
hulle  deur die verpleegpersoneel 
behandel word nie 1 2 3 4 
051_get
offwork 
Pasiënte woon nie hul kliniek afsprake na 
nie, omdat hulle nie tyd kan afkry by die 
werk nie. 1 2 3 4 
052_HC
Wtime 
Pasiënte woon nie hul kliniek afsprake na 
nie omdat die wagperiodesom die dokter, 
verpleegster of apteker te sien te lank is..  1 2 3 4 
053_uns
afetowal
k 
Pasiënte woon nie hul kliniek afsprake na 
nie omdat hulle onveilig voel om na en 
van die kliniek af te stap.   1 2 3 4 
054_cro
wdedcli
nic 
Pasiënte woon nie hul kliniek afsprake na 
nie, omdat die kliniek oorvol is. 
1 2 3 4 
055_spe
aklang 
Pasiënte woon nie hul kliniek afsprake na 
nie, omdat die verpleegsters nie hul taal 
praat nie. 1 2 3 4 
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Addendum E: Barriers to PATIENTS’ medication taking: SBS-4 
Below are some reasons that OTHER patients MAY NOT TAKE THEIR ART MEDICATION. 
Please indicate to what extent YOU THINK these statements are true for people receiving 
medicines for HIV. Please circle or mark one number per line to indicate your response. 
    
Not true 
for 
 any 
patients 
True 
for  
some 
patients 
True 
for  
most 
patients 
True 
for  
all 
patients 
056_nofood 
 Patients do not take their 
ART pills because  
they do not always have food 
with which to take them. 1 2 3 4 
057_food/ill 
 If patients take their ART 
pills when they  
do not have food to eat then 
they often feel ill. 1 2 3 4 
058_stigma7 
 Patients do not take their 
ART pills if  
they have to take it in front of 
others. 1 2 3 4 
059_reminders 
 Patients do not take their 
ART pills because  
they do not have a way to 
remind themselves to take 
them. 1 2 3 4 
060_employers 
 Patients do not take their 
ART pills because 
 they do not want their 
employers to know that they 
are HIV positive. 1 2 3 4 
061_forgetting 
 Patients do not take their 
ART pills because 
 they forget to do so. 1 2 3 4 
063_Churches 
 Patients do not take their 
ART pills because 
 the church pastors have told 
them not to. 1 2 3 4 
064_drinking 
 Patients forget to take their 
ART pills  
when they drink alcohol.  1 2 3 4 
065_remindersupport 
 Patients do not take their 
ART pills because  
they do not have someone to 1 2 3 4 
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remind them to take it. 
066_Thealing 
 Patients do not take their 
ART pills because  
they believe traditional 
healing works better for 
them. 1 2 3 4 
067_affordfood 
 Patients do not take their 
ART pills because  
they cannot afford the food 
they need in order to take it. 1 2 3 4 
068_disability 
 Patients do not take their 
ART pills in case their 
 CD4 count increases and 
they no longer qualify for a 
disability grant. 1 2 3 4 
070_stigma8 
 Patients do not take their 
ART pills because they 
 do not like taking it in front 
of their families.  1 2 3 4 
 
Hier is 'n paar redes waarom ANDER pasiënte NIE HUL ART MEDIKASIE gebruik nie. Dui 
asseblief aan watter mate dink jy dat hierdie stellings waar is vir die mense wat medisyne vir 
MIV ontvang. Sirkel asseblief of merk een getal per lyn om jou antwoord aan te dui. 
  
Nie 
waar 
 vir 
enige 
pasië
nte 
Waa
r vir  
som
mige 
pasië
nte 
Geld 
vir 
die  
mees
te 
pasië
nte 
Geld 
vir  
alle 
pasië
nte 
056_nofood 
Pasiënte neem nie hul ART pille nie omdat hulle 
nie altyd voedsel het om saam dit te neem nie. 1 2 3 4 
057_food/ill 
As pasiënte hul ART pille sonder voedsel neem 
dan voel hulle dikwels siek.  1 2 3 4 
058_stigma7 
Pasiënte neem nie hul ART pille as hulle dit 
voor die ander moet neem nie.  1 2 3 4 
059_reminde
rs 
Pasiënte neem nie hul ART pille nie, omdat 
hulle nie self 'n manier het om hul daaraan te 
herinner om hulle te neem nie.  1 2 3 4 
060_employe
rs 
Pasiënte neem nie hul ART pille nie, omdat 
hulle nie wil hê dat hul werkgewers weet dat 1 2 3 4 
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hulle MIV-positief is nie.  
061_forgettin
g 
Pasiënte neem nie hul ART pille nie, omdat 
hulle vergeet om dit te doen.. 1 2 3 4 
063_Churche
s 
Pasiënte neem nie hul ART pille nie, omdat 
hulle kerkpastore hulle vertel het om dit nie te 
neem nie. 1 2 3 4 
064_drinking Pasiënte vergeet om hulle ART pille te neem as 
hulle alkohol drink. 1 2 3 4 
065_reminde
rsupport 
Pasiënte neem nie hul ART pille nie, omdat 
hulle nie iemand het om hul daaran te herinner 
nie.  1 2 3 4 
066_Thealin
g 
Pasiënte neem nie hul ART pille nie, omdat 
hulle glo tradisionele genesing  beter vir hulle 
werk.  1 2 3 4 
067_affordfo
od 
Pasiënte neem nie hul ART pille nie, omdat 
hulle nie die kos wat hulle nodig  kan bekostig 
om saam met dit te neem nie.  1 2 3 4 
068_disabilit
y 
Pasiënte neem nie hul ART pille nie in die geval 
dat hul CD4 verhoog is ek nie langer kan 
kwalifiseer vir die ongeskiktheids-toelaag nie. 1 2 3 4 
070_stigma8 Pasiënte neem nie hul ART pille nie, omdat 
hulle nie daarvan hou om dit voor hul gesinne te 
neem nie.  1 2 3 4 
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Addendum F: Participant flyer 
 
 
 
 
PLEASE JOIN THIS 
STUDY! 
Assessing Barriers to 
adherence to ART 
You are invited to participate in a 
study conducted by Stellenbosch 
University! All you have to do is 
complete a few forms and you will 
receive a R20 shopping voucher!! 
 
INTERESTED? 
Please come and find the 
research assistant  
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Addendum G: Participant informed consent form 
 
PARTICIPANT INFORMATION LEAFLET AND CONSENT FORM 
 
 
TITLE OF THE RESEARCH PROJECT: 
 
THE DEVELOPMENT OF A SCALE TO ASSESS STRUCTURAL BARRIERS TO 
ANTIRETROVIRAL THERAPY ADHERENCE 
 
PRINCIPAL INVESTIGATOR: 
BRONWYNE COETZEE 
 
ADDRESS: 
28 FIR ROAD OAK GLEN BELLVILLE 7530 
 
CONTACT NUMBER: 
0722415028 
 
You are being invited to take part in a research project.  Please take some time to read the 
information presented here, which will explain the details of this project.  Please ask the study 
staff or doctor any questions about any part of this project that you do not fully understand.  It is 
very important that you are fully satisfied that you clearly understand what this research entails 
and how you could be involved.  Also, your participation is entirely voluntary and you are free 
to decline to participate.  If you say no, this will not affect you negatively in any way 
whatsoever.  You are also free to withdraw from the study at any point, even if you do agree to 
take part. 
 
This study has been approved by the Health Research Ethics Committee (HREC) at 
Stellenbosch University and will be conducted according to the ethical guidelines and principles 
of the international Declaration of Helsinki, South African Guidelines for Good Clinical Practice 
and the Medical Research Council (MRC) Ethical Guidelines for Research. 
 
What is this research study all about? 
The following study will be conducted at Helderberg Hospital, Ikhwezi Hospital and at the 
Philippi Trust (NGO) in Somerset West. Approximately 200 participants will be invited to take 
part in this study. The following study aims to develop a scale that can identify barriers that you 
as a patient experience when taking you ARV medication. The scale will help doctors and nurses 
to identify difficulties that you face and are then able to help you in overcoming them. If you 
agree to participate in this study you will complete 1. Demographic information. 2. The 
structural Barriers scales. 3. The functional assessment of HIV. 4. The SF-12 and lastly 5. The 
HSCL-25. 
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Why have you been invited to participate? 
You have been invited to participate in this study because:  
1. You have been diagnosed with a chronic illness.  
2. You have been prescribed medication to control your illness.  
 
 
What will your responsibilities be? 
As a participant in this study you will have no direct responsibilities.  
 
Will you benefit from taking part in this research?  
As a participant it is not intended that you will benefit directly from this research. However, if 
the scale proves to identify structural barriers adequately clinicians will be able to help you and 
future patients with difficulties you face when taking your medication or attending clinic 
appointments. Your participation will help the researchers further their understanding of ART 
adherence.  
 
* Are there in risks involved in your taking part in this research? 
There are no foreseeable risks and you may stop your participation at any time. Should you 
become distressed at any point during the completion of the questionnaires you will be given 
information about where to seek psychological services. Should your involvement in the study 
cause severe psychological distress as any point, you will be referred to a trained counsellor. The 
costs concerned with treatment will be taken care of by the principal investigator.  
 
If you do not agree to take part, what alternatives do you have? 
If you do not wish to participate in the study, you are not obliged to continue in anyway. There 
are no alternatives available to this study. 
 
Who will have access to your medical records? 
The use of your medical records is not applicable to this study and therefore no one will have 
access to your records. 
 
*What will happen in the unlikely event of some form injury occurring as a direct result of 
your taking part in this research study? 
This study poses no physical threat to you. Should any unforeseeable events occur the necessary 
services will be provided. Should your involvement in the study cause severe psychological 
distress as any point, you will be referred to a trained counsellor. The costs concerned with 
treatment will be taken care of by the principal investigator.  
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Will you be paid to take part in this study and are there any costs involved? 
 
No you will not be paid to take part in the study but you will receive a R20 shopping voucher to 
thank you for your participation. There will be no costs involved for you, if you do take part. 
 
You can contact Bronwyne Coetzee at cell: 072 241 5028 if you have any further queries or 
encounter any problems. 
You can contact the Health Research Ethics Committee at 021-938 9207 if you have any 
concerns or complaints that have not been adequately addressed by your study doctor. 
You will receive a copy of this information and consent form for your own records. 
 
 
 
Declaration by participant 
 
By signing below, I …………………………………..…………. agree to take part in a research 
study entitled (insert title of study). 
 
I declare that: 
 
 I have read or had read to me this information and consent form and it is written in a 
language with which I am fluent and comfortable. 
 I have had a chance to ask questions and all my questions have been adequately 
answered. 
 I understand that taking part in this study is voluntary and I have not been 
pressurised to take part. 
 I may choose to leave the study at any time and will not be penalised or prejudiced in 
any way. 
 I may be asked to leave the study before it has finished, if the study doctor or 
researcher feels it is in my best interests, or if I do not follow the study plan, as 
agreed to. 
 
 
Signed at (place) ......................…........…………….. On (date) …………....……….. 2009. 
 
 
 
......................................................................   ...................................................................  
Signature of participant Signature of witness 
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Declaration by investigator 
 
I Bronwyne Coetzee……………………………………………..……… declare that: 
 
 I explained the information in this document to ………………………………….. 
 I encouraged him/her to ask questions and took adequate time to answer them. 
 I am satisfied that he/she adequately understands all aspects of the research, as 
discussed above 
 I did/did not use an interpreter.  (If an interpreter is used then the interpreter must 
sign the declaration below. 
 
 
Signed at (place) ......................…........…………….. On (date) …………....……….. 2009. 
 
 
 
......................................................................   ...................................................................  
Signature of investigator Signature of witness 
 
 
Declaration by interpreter 
 
I (name) ……………………………………………..……… declare that: 
 
 I assisted the investigator (name) ………………………………………. to explain 
the information in this document to (name of participant) 
……………..…………………………….. using the language medium of 
Afrikaans/Xhosa. 
 We encouraged him/her to ask questions and took adequate time to answer them. 
 I conveyed a factually correct version of what was related to me. 
 I am satisfied that the participant fully understands the content of this informed 
consent document and has had all his/her question satisfactorily answered. 
 
 
Signed at (place) ......................…........…………….. on (date) …………....……………….. 
 
 
 
......................................................................   ...................................................................  
Signature of interpreter Signature of witness 
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DEELNEMERINLIGTINGSBLAD EN -TOESTEMMINGSVORM 
 
 
TITEL VAN DIE NAVORSINGSPROJEK: 
 
DIE ONTWIKKELING VAN ‘N SKAAL OM STRUKTURELE HINDERNISSE TOT 
ANTIRETROVIRALE TERAPIE TE ASSESSEER 
 
 
HOOFNAVORSER: 
 
BRONWYNE COETZEE 
 
ADRES: 
 
28 FIR LAAN OAKGLEN BELLVILLE 7530 
 
KONTAKNOMMER: 
 
U word genooi om deel te neem aan ‟n navorsingsprojek.  Lees asseblief hierdie inligtingsblad 
op u tyd deur aangesien die detail van die navorsingsprojek daarin verduidelik word.  Indien daar 
enige deel van die navorsingsprojek is wat u nie ten volle verstaan nie, is u welkom om die 
navorsingspersoneel of dokter daaroor uit te vra.  Dit is baie belangrik dat u ten volle moet 
verstaan wat die navorsingsprojek behels en hoe u daarby betrokke kan wees.  U deelname is ook 
volkome vrywillig en dit staan u vry om deelname te weier.  U sal op geen wyse hoegenaamd 
negatief beïnvloed word indien u sou weier om deel te neem nie.  U mag ook te eniger tyd aan 
die navorsingsprojek onttrek, selfs al het u ingestem om deel te neem. 
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Hierdie navorsingsprojek is deur die Komitee vir Mensnavorsing van die Universiteit 
Stellenbosch goedgekeur en sal uitgevoer word volgens die etiese riglyne en beginsels van 
die Internasionale Verklaring van Helsinki en die Etiese Riglyne vir Navorsing van die 
Mediese Navorsingsraad (MNR). 
 
Wat behels hierdie navorsingsprojek? 
Die volgende studie sal gedoen word by Helderberg Hospitaal, Ikhwezi-hospitaal en by die 
Philippi Trust (NRO's) in Somerset-Wes. Ongeveer 200 deelnemers sal genooi word om deel te 
neem aan hierdie studie. Die doel van hierdie studie is om n skaal te ontwikkel wat die 
strukturele hindernisse wat u as pasient ervaar wanneer u ARV-medisyne neem te identifiseer.     
Die skaal sal dokters en verpleegsters help om struikelblokke wat u nakom te identifiseer en dan 
u hulp dit oorkom . As U deel neem aan hierdie studie sal u die volgende voltooi 1. Persoonlike 
inligtig 2. Die strukturele Hinderniss Skaal 3. Die FAHI 4. Die SF12V2 en 5. Die HSCL-25. 
Waarom is u genooi om deel te neem? 
U is uitgenooi om deel te neem aan hierdie studie omdat: 
1.  U gediagnoseer is met 'n chroniese siekte.  
2.  U gebruik  voorgeskrewe medikasie om U siekte te beheer. 
Wat sal u verantwoordelikhede wees? 
As „n deelnemer aan hierdie studie het u geen direkte verantwoordelikhede nie. 
Sal u voordeel trek deur deel te neem aan hierdie navorsingsprojek? 
As 'n deelnemer is dit nie bedoel dat u direk sal baat uit hierdie navorsing nie. Maar, as die skaal 
bewys om strukturele hindernisse voldoende te identifiseer sal klinici in staat  wees om met u en 
toekomstige pasiënte se probleme met die neem van medikasie of bywoning van jou kliniek 
afsprake te help. Jou deelname sal navorsers help om ART behandeling beter te verstaan. 
 
Is daar enige risiko's verbonde aan u deelname aan hierdie navorsingsprojek? 
 Daar is geen voorsienbare risiko's nie en jy kan om enige tyd jou deelname aan die studie stop.  
As u ongemaklik of benoud  raak op enige tyd tydens die voltooiing van die vraelyste, sal  
inligting oor  sielkundige dienste aan u verskaf word. Indien u betrokkenheid by die studie 
ernstige sielkundige nood benodig , sal u verwys word na' n opgeleide berader.  Die koste 
betrokke by die behandeling sal verskaf word deur die hoof ondersoeker.  
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Watter alternatiewe is daar indien u nie instem om deel te neem nie? 
 As u nie wil deelneem aan die studie nie, is u nie verplig om voort te gaan nie. Daar is geen 
alternatiewe beskikbaar vir die studie nie.  
 
Wie sal toegang hê tot u mediese rekords? 
Die gebruik van u mediese rekords is nie van toepassing op hierdie studie nie, en dus sal 
niemand toegang tot u rekords he nie.  
 
Wat sal gebeur in die onwaarskynlike geval van ’n besering wat mag voorkom as gevolg 
van u deelname aan hierdie navorsingsprojek? 
Hierdie studie het geen fisiese bedreiging tot u nie.  Indien enige onvoorsiene gebeure plaasvind 
sal die nodige dienste voorsien word.  Indien u betrokkenheid by die studie ernstige sielkundige 
nood benodig, sal u verwys word na' n opgeleide berader.  Die koste betrokke by die behandeling 
sal verskaf word deur die hoof ondersoeker. 
 
Sal u betaal word vir deelname aan die navorsingsprojek en is daar enige koste verbonde 
aan deelname? 
 Nee u sal nie betaal word om deel te neem aan die studie, maar u sal 'n R20 geskenkbewys 
ontvang om u te bedank vir u deelname.  Daar sal geen koste aan u verbonde wees om aan die 
studie deel te neem nie.  
 U kan  Bronwyne Coetzee kontak by 072 241 5028 indien u enige verdere navrae of probleme.  
U kan die Komitee vir Mensnavorsing kontak by 021-938 9207 indien u enige bekommernis of 
klagte het wat nie bevredigend deur u studiedokter hanteer is nie. 
U sal ‟n afskrif van hierdie inligtings- en toestemmingsvorm ontvang vir u eie rekords. 
Verklaring deur deelnemer 
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Met die ondertekening van hierdie dokument onderneem ek, 
…….....................……….....……...……….., om deel te neem aan ‟n navorsingsprojek getiteld  
(Titel van navorsingsprojek). 
 
Ek verklaar dat: 
 
 Ek hierdie inligtings- en toestemmingsvorm gelees het of aan my laat voorlees het en 
dat dit in ‟n taal geskryf is waarin ek vaardig en gemaklik mee is. 
 Ek geleentheid gehad het om vrae te stel en dat al my vrae bevredigend beantwoord 
is. 
 Ek verstaan dat deelname aan hierdie navorsingsprojek vrywillig is en dat daar geen 
druk op my geplaas is om deel te neem nie. 
 Ek te eniger tyd aan die navorsingsprojek mag onttrek en dat ek nie op enige wyse 
daardeur benadeel sal word nie. 
 Ek gevra mag word om van die navorsingsprojek te onttrek voordat dit afgehandel is 
indien die studiedokter of navorser van oordeel is dat dit in my beste belang is, of 
indien ek nie die ooreengekome navorsingsplan volg nie. 
 
 
Geteken te (plek) ..............................…………….. op (datum) …………....……….. 2005. 
 
 
 
......................................................................   ...................................................................  
Handtekening van deelnemer Handtekening van getuie 
 
 
Verklaring deur navorser 
 
Ek Bronwyne Coetzee verklaar dat: 
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 Ek die inligting in hierdie dokument verduidelik het aan 
…………………….............................................……….. 
 Ek hom/haar aangemoedig het om vrae te vra en voldoende tyd gebruik het om dit te 
beantwoord. 
 Ek tevrede is dat hy/sy al die aspekte van die navorsingsprojek soos hierbo bespreek, 
voldoende verstaan. 
 Ek ‟n tolk gebruik het/nie ‟n tolk gebruik het nie.  (Indien ’n tolk gebruik is, moet die 
tolk die onderstaande verklaring teken.) 
 
 
Geteken te (plek) ..............................…………….. op (datum) …………....……….. 2005. 
 
 
 
......................................................................   ...................................................................  
Handtekening van navorder Handtekening van getuie 
 
Verklaring deur tolk 
 
Ek (naam) …………………………………...……………… verklaar dat: 
 
 Ek die navorser (naam) ……….............................…………………. bygestaan het 
om die inligting in hierdie dokument in Afrikaans/Xhosa aan (naam van deelnemer) 
……………………………......................... te verduidelik. 
 Ons hom/haar aangemoedig het om vrae te vra en voldoende tyd gebruik het om dit 
te beantwoord. 
 Ek ‟n feitelik korrekte weergawe oorgedra het van wat aan my vertel is. 
 Ek tevrede is dat die deelnemer die inhoud van hierdie dokument ten volle verstaan 
en dat al sy/haar vrae bevredigend beantwoord is. 
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Geteken te (plek) ..............................…………….. op (datum) …………....……….. 2005. 
 
 
 
......................................................................   ...................................................................  
Handtekening van tolk Handtekening van getuie 
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Addendum H: Health Research Ethics Committee of the University of Stellenbosch 
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Addendum I: The Western Cape Department of Health  
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Addendum J: The City of Cape Town  
 
 
 
 
C I T Y  H E A L T H  — City Health 
 
2010-05-07 
Re:  Research Request:  The development of an inventory to assess structural barriers to adherence to 
antiretroviral therapy (ID:  10174) 
 
Dear Ms Coetzee, 
Permission has been granted for you to do the research as per your protocol at Ikhwezi Clinic subject to 
space being available. 
 
Contact People: 
Dr P Nkurunziza:  Sub District Manager:  Eastern Sub District 
    Tel/Cell:  (021) 850-4315 / 084 800 0644 
Ms T Mgqweto:  Head:  Personal PHC & Programme 
    Tel/Cell:  (021) 850-4312 / 084 222 1487 
 
Please note the following: 
1.  Space at Ikhwezi Clinic is very problematic and this will have to be negotiated with the relevant 
Managers.  Researchers often hire space from other organisations close to the clinic e.g. schools 
or NPO’s 
2. All individual patient information obtained must be kept confidential. 
3. Access to the clinic and its patients must be arranged with the relevant Manager such that 
normal activities are not disrupted. 
4. A copy of the final report must be sent to the City Health Head Office, P O Box 2815 Cape Town 
8001, within 3 months of its completion and feedback must also be given to the clinic involved. 
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5. Your project has been given an ID Number (10174).  Please quote this in any future 
correspondence regarding this project. 
 
Thank you for your co-operation and contact me if you require any further information or assistance. 
 
Yours sincerely 
Dr G H Visser 
Manager:  Specialised Health  
cc. Dr P Nkurunziza & Ms T Mgqweto 
 Dr K Jennings 
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